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ABSTRACT 
Diseases of the posterior segment of the eye such as diabetic retinopathy, age related 
macular degeneration and glaucoma are the leading causes for blindness throughout the world. 
Topical eye drops is the most convenient formulation for daily application. The human eye, 
however, presents major physiological and dynamic barriers for the topically administered 
drug/molecule from reaching the retina. Similarly, the blood-retinal and blood-aqueous barriers 
restricts passage of drug from systemic circulation into the eye. Although intravitreal injections 
are the gold standards for the treatment of posterior segment ocular diseases, they are associated 
with pain, inflammation, endopthalmitis and infection. So there is a necessity to develop novel 
noninvasive drug delivery strategies to treat the posterior segment ocular diseases. 
 In the present study, we have used melt cast technology to develop a polymeric matrix film 
system to deliver Hesperetin (HT), a bioflavanoid, to the posterior segment of the eye. The film is 
4 mm x 2 mm in dimension and 0.2 to 0.4 mm in thickness. When the HT-film was tested in vivo 
in anesthetized rabbit model, HT levels were maintained above the neuroprotective and anti-
inflammatory IC50 levels for upto 6 h. We also prepared HT loaded (0.1% w/v) solid lipid 
nanoparticles (SLN’s) using a combination of 85% glyceryl monostereate and 15% compritol ATO 
888. The particle size, zeta potential and entrapment efficiency of the HT-SLN’s was 225 nm, -21 
mV and 85% respectively. Although the dose administered in the animal study was approximately 
16-fold lower than the HT-Film, SLN’s provided very good HT levels in the anterior segment of 
the eye. These formulations were tested in the conscious animal model to determine the effect of 
active lymphatic and tear drainage. Significant elimination of HT was observed in the aqueous 
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humor due to the turnover rate (1.0% to 1.5% of the anterior chamber volume per minute). But the 
film formulation was able to maintain 2.3 µg of HT/gm of tissue in the retina choroid and 80 ng 
of HT/gm of vitreous humor upto 3 h. SLN’s were able to deliver 1.9 µg of HT/gm of iris ciliary 
bodies, but HT levels were below detection limit in the posterior segment of the eye. Thus, 
polymeric matrix films prove to be a safe and effective platform for the delivery of drugs/drug 
candidates to the posterior segment of the eye. 
Glaucoma is the second leading cause for blindness worldwide. Rise in intraocular pressure 
(IOP) has been identified as an important risk factor in the pathogenesis of the disease. Δ9-
Tetrahydrocannabinol (THC), an active ingredient of the plant cannabis sativa, and an agonist of 
the cannabinoid receptors, CB1 and CB2, could potentially be such a dual acting anti-glaucoma 
agent. Delivering therapeutic levels of THC into the inner ocular layers is very challenging due to 
the extremely lipophilic characteristics of THC. A synthetic amino acid dicarboxylic acid prodrug 
of THC, Δ9-Tetrahydrocannabinol valine hemisuccinate (THC-Val-HS) was developed. Micellar 
and nanoemulsion formulations of THC-Val-HS and THC were prepared. These formulations 
were evaluated for IOP reduction in an alpha chymotrypsin induced rabbit glaucoma model. With 
the 0.5%w/v THC emulsion formulation drop in IOP was observed at 30 min, but was very 
minimal and short acting (60 min). With an increase in dose (0.8% w/v THC) a similar effect was 
observed with a slight increase in the duration of activity (90 min). With THC-Val-HS (0.6% w/v 
THC equivalent), drop in IOP was observed at 30 min, but the maximum drop was observed at 90 
min, lasting upto 3 h (90% of the baseline). The more gradual drop in IOP can be attributed to the 
fact that THC-Val-HS has to be enzymatically converted into THC to show activity. Receptor 
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binding studies revealed that THC-Val-HS has 21.8 and 38 folds less affinity towards CB1 and 
CB2 receptors, respectively, than THC. Thus, the present study demonstrates that a rational 
combination of prodrug design and formulation strategies can effectively deliver THC to the 
anterior chamber of the eye. An increased IOP reduction with the prodrug at lower equivalent 
doses of THC, supports improved ocular penetration of the prodrug. Importantly, with most of the 
conventionally developed anti-glaucoma drugs having no reported neuroprotective action, THC, 
an established neuroprotectant, has the potential to become an effective glaucoma medication. 
Further studies are currently aimed at developing and optimizing various formulations with 
improved THC delivery to the back-of-the eye. 
Since the rate of elimination of drug candidates was relatively rapid in the earlier studies, 
ion exchange resin - drug complexes were incorporated into the matrix film to improve the 
sustained release profile. Ion exchange resins (IR) are water insoluble cross linked polymers with 
ionizable groups that can be exchanged to form complexes. Diclofenac sodium (DFS) was used as 
a model drug. The goal of this study was to develop polymeric matrix films loaded with a 
combination of free diclofenac sodium (DFS) and DFS-Ion exchange resin (IR) complexes for 
immediate and sustained release profiles, respectively. Complexation efficiency of DFS-IR was 
found to be 99% at 1:1 ratio of DFS:IR. Solution and DFS:IR suspension formulations were not 
able to maintain therapeutic DFS levels in AH and other ocular tissues. The matrix film, as such, 
was able to achieve high levels of DFS in the ocular tissues, but was not able to overcome the rapid 
elimination profile. On the other hand, DFS:IR loaded matrix films were able to maintain DFS 
levels in the inner ocular tissues fairly constant for upto 8h, probably because of continuous release 
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of DFS from the IR and retention of the IR complexes on the ocular surface. Thus, drug IR 
complexes loaded into matrix films could be a potential sustained ocular delivery platform.
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CHAPTER 1 
1.1. INTRODUCTION: 
The ‘eye’ is a specialized sensory organ which responds to light and gives us the visual 
perception of our surrounding environment.  The anatomy of eye and the routes of drug delivery 
pertaining to eye are shown in the Figure 1.1. Human eye is divided into two major segments: the 
anterior segment 
and the posterior 
segment. 
 The major 
parts of anterior 
segment are 
cornea, trabecular 
meshwork and 
schlemm’s canal, 
anterior uvea (iris, 
pupil and ciliary 
body), aqueous humor and lens. The posterior segment of the eye consists of sclera, choroid, retina, 
vitreous humor and optic nerve. It is the retina where the visual information is collected by the 
rods and cones and passed on to the optic nerve for processing in the central nervous system. Age, 
disease and injury may cause temporary or permanent damage to the eye. Although, damage to the 
Figure 1.1: Anatomical structure of the human eye. 
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anterior segment of the eye may sometimes leads to permanent damage, they can, however be 
treated by proper medication.  
1.1.1. Posterior segment ocular diseases: 
A report from the World Health Organization (WHO) in 2011 estimated that approximately 285 
million people were suffering from visual impairment worldwide out of which 39 million face 
blindness while 246 million suffer from moderate to severe vision impairment. With an increase 
in the average survival age and the percentage of diabetics, diabetes related retinopathies are 
rapidly gaining in significance. It has been predicted that, without additional steps, these numbers 
will increase to 75 million blind and 200 million visually impaired by the year 2020 (WHO, 2010). 
Age seems to be a causative factor in blindness as 90% and 58% of the population with blindness 
are aged above 45 and 60 years respectively [1].  
 Oxidative stress, inflammatory mechanisms and decreased antioxidant capacity in the 
ocular tissues are all thought to play an active role in the development and progression of these 
ocular diseases. The following sections briefly highlight the etiology of these ocular disorders, 
followed by discussions on the therapeutic potential of various phytochemicals and challenges 
encountered in their delivery to the ocular tissues. 
Diabetic Retinopathy 
 Diabetic retinopathy (DR) is the most common diabetes associated eye disease and is the 
leading cause of blindness in American adults [2, 3]. The WHO estimates that over 360 million 
worldwide will suffer from diabetes by the year 2030. Currently, 10% of the diabetics suffer from 
Type I diabetes whereas 90% suffer from Type 2 diabetes. DR in Type 1 diabetics approaches 80 
and 90 % prevalence rate after 10 and 20 years of diabetes, respectively. Up to 21% of patients 
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with Type 2 diabetes have recently been found to have retinopathy at the time of first diagnosis of 
diabetes, and most develop some degree of retinopathy over subsequent decades [4]. 
 DR can be broadly categorized into three stages; background DR, pre-proliferative DR and 
proliferative DR (PDR) [5-7]. In background DR, hyperglycemia is considered to induce 
thickening of capillary basement membranes and death of pericytes, which support the vessel wall, 
and endothelial cells of retinal blood vessels. Microaneurysms and vascular leakage follow, and 
blockage of retinal capillaries take place. In pre-proliferative DR, loss of vascular patency leads to 
areas of increasing retinal hypoxia and multiple hemorrhages. Increased areas of tissue non-
perfusion stimulate the production of angiogenic factors leading to the proliferation of vessels, 
which is a typical feature of PDR. The newly formed blood vessels by themselves do not lead to 
vision loss, but leakage of blood through their weak walls can result in severe vision loss and can 
ultimately lead to complete loss of sight. 
 Hyperglycemia and tissue hypoxia, are considered to be principal factors in the DR 
pathology described above. Multiple studies demonstrate the relationship between high blood 
glucose, oxidative stress and initiation of DR [7-12]. The retina is highly susceptible to oxidative 
damage since: a) it has an abundance of the polyunsaturated fatty acids in its membrane bilayers, 
whose double bonds are prime targets for peroxidation reactions; b) it is periodically subjected to 
continuous light which, by photoexcitation, can initiate free radical formation and peroxidation 
reactions and c) the retina is a highly metabolic tissue that requires a high rate of blood flow in 
order to receive an adequate oxygen supply. Oxidative damage in biological systems occurs when 
endogenous antioxidant mechanisms are overwhelmed by free oxygen radicals or reactive oxygen 
species (ROS). These radicals are extremely unstable and can cause cytotoxicity and cellular 
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damage by reacting with plasma membrane lipids, DNA, RNA and metal-containing compounds 
[13].  
 Multiple pathways have been suggested to be activated during hyperglycemia associated 
oxidative stress, which subsequently leads to damage of retinal blood vessels. These include nitric 
oxide (NO) synthesis [14, 15], NF-κβ expression, secretion of cytokines such as IL-1β, lipid 
peroxide generation, activation of retinal caspase-3, protein kinase C (PKC) stimulation and 
alterations of retinal glutamate levels [13, 16-21]. 
In advanced stages, i.e. PDR, reduced retinal blood flow induces retinal ischemia which 
leads to hypoxic conditions in the retina. Hypoxia stimulates production of a variety of local agents 
including vascular endothelial growth factor (VEGF) [7, 22-26], prostaglandins, cyclooxygenase-
2 (COX-2) and nitric oxide (NO), all of which participates in increasing vascular permeability and 
angiogenesis [7]. The VEGF family plays a key role in the regulation of vascular patency and is 
involved in both physiological and pathological angiogenesis, stimulating endothelial cells to 
migrate, proliferate and form tubes [7, 27-30]. VEGF is also a potent vascular bed permeability 
enhancer [31, 32]. Hypoxia is a stimulant for COX-2 transcription also in various tissues [7, 33-
35], including human vascular endothelium [7, 33] and neural cells [36]. NF-kβ, an oxygen 
sensitive transcription factor [7, 37, 38] mediates the induction of COX-2 in hypoxic conditions. 
The angiogenic properties of COX-2 are likely to directly involve VEGF, as COX-2 has been 
shown to up-regulate VEGF synthesis which can be inhibited with selective or non-selective COX 
inhibitors [7, 39, 40]. 
In the context of DR, the actions of prostaglandins E2 and I2 are also considered to be 
important in the development of angiogenesis, breakdown of the blood-retinal barrier and 
alterations in retinal blood flow [7, 41-46]. These prostaglandins are produced via the COX-2 
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pathway, [7, 47-49]. Prostaglandins, and in particular PGE2, are also strong inducers of VEGF in 
cell types such as synovial fibroblasts monocytes and lung and retinal Müller cells. There is 
evidence that the vascular events prior to angiogenesis may involve the induction of COX-2 
followed by VEGF. It has thus been suggested that angiogenesis may be mediated by dual 
interdependent gene expression pathways that involve COX-2 and VEGF [7, 50].   
NO is known to participate in vascular permeability and angiogenesis via interactions with 
VEGF and COX-2. NO reacts with superoxide anions to form peroxynitrite, a highly reactive 
oxidant. Excess production of peroxynitrite in diabetes may exhibit cytotoxic effects by increasing 
DNA damage, stimulating lipid peroxidation and depleting glutathione levels [51-53]. Peroxynitrite 
alters tyrosine in proteins to form nitrotyrosine and nitration of proteins can inactivate 
mitochondrial and cytosolic proteins and damage cellular elements leading to nitrative stress [54]. 
PDR is the most damaging stage of DR as it leads to the generation of abnormally located retinal 
blood vessels with weak capillary walls. Microvascular leakage from these newly formed blood 
vessels can lead to total blindness through a variety of mechanisms. 
 In addition to hyperglycemia associated increased ROS generation, it has recently been 
demonstrated that the Total Antioxidant Capacity (TAC) of the vitreous humor and aqueous humor 
is lowered in DR. Mancino et al. determined the antioxidant capacity of blood, aqueous humor and 
vitreous of controls (non-diabetic) and of patients with non-proliferative DR (NPDR) and with 
proliferative DR (PDR) [55]. The authors observed that the control group displayed significantly 
higher TAC levels than the diabetic sub-groups in both the vitreous and aqueous humor. PDR 
patients had decreased TACs in the vitreous and aqueous humor as compared with control subjects 
and with the NPDR patient subgroup, pointing to the role of oxidative stress in the progression of 
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NPDR to PDR [55]. The results strongly support the need for increased antioxidant levels in the 
retina, aqueous humor and vitreous humor. 
 
Age-Related Macular Degeneration 
Age-related macular degeneration (AMD), which can be categorized into dry and wet 
AMD, is the leading cause of irreversible vision loss in the developed world. As per the statistical 
data published by the National Eye Institute, AMD affected 1.75 million persons in the United 
States, in 2004, a number which is expected to rise to nearly 3 million by 2020 due to the aging of 
the population [56]. Like DR, progression of AMD is linked to the activation of inflammatory and 
immunological pathways [57]. Presence of excess ROS and decreased antioxidant capacity in the 
ocular tissues is also considered to play a significant role in the initiation and progression of AMD 
[58, 59]. Ding et al provides a summary of the molecular pathways involving inflammation, 
angiogenesis and oxidative stress, considered  to play a role in the development of AMD [60]. 
Cataract 
Oxidative stress induced damage to the lens fibers has also been well documented. It is 
thought that these free radicals accelerate and aggravate cataract development. Additionally, 
diabetic lenses show an impaired antioxidant capacity that increases their susceptibility to 
oxidative stress. The loss of antioxidants is exacerbated by glycation and inactivation of lens 
antioxidant enzymes like superoxide dismutase [61]. 
Glaucoma 
  Glaucoma is caused when the aqueous humor builds up in the anterior chamber. This 
causes increased pressure in the anterior chamber of the eye which is passed on to the posterior 
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segment of the eye. Elevated intraocular pressure on the retina causes imbalance in adaptive cell 
response (ant-oxidant system, anti-proteolytic system and adaptive gene expression) and cell death 
(genetic mutation, chronic and acute oxidative stress, apoptosis and mechanical stress) leading to 
retinal ganglion cell death and blindness. 
1.2. Challenges in drug delivery to the posterior segment of the eye: 
The eye is a secluded organ, protected by various physiological barriers that restrict entry 
of xenobiotics into the ocular tissues from the external environment (topical or periocular) or 
systemic circulation (Table 1.1). The choroidal blood vessels possess many large fenestrations 
and pinocytic vesicles that allow free exchange of endogenous/exogenous substances between the 
choroidal stroma and choroidal vasculature. 
Thus, systemically administered therapeutic agents can easily diffuse out into the choroidal 
stroma from the systemic circulation [62]. Bruch’s membrane, separating the choroid from the 
RPE, acts as a barrier to the diffusion of only macromolecules, like proteins and genes, and thus 
does not pose much of a diffusional barrier to small molecules. The retinal pigmented epithelium 
(RPE), on the other hand, presents a formidable permeation barrier to small drug molecules in their 
diffusion into the neural retina and vitreous humor from the choroidal stroma [62-64]. Epithelial 
cells of the RPE are joined together by tight junctions [65-69] similar to those observed in the 
blood-brain barrier, severely restricting paracellular diffusion of hydrophilic molecules. The RPE 
cells also express the efflux proteins P-gp and MRP on the basolateral membrane [70-73]. As a 
result, trans-retinal permeation of compounds that are substrates of these efflux proteins, from the 
systemic circulation (choroidal side) into the neural retina/vitreous humor, is strongly modulated 
by RPE P-gp/MRP mediated efflux. The RPE, thus, presents a major barrier to the exchange of 
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therapeutic agents between the choroidal stroma and the neural retina / vitreous humor, and is 
referred to as the outer BRB.  
 
Similar to the RPE, the endothelial cells of the blood vessels perfusing the neural retina express 
efflux proteins and tight-junction proteins [64, 74]. The efflux proteins are polarized on the apical 
Table 1.1: Route of administration dependent physiological barriers encountered in the 
diffusion path to the neural retina. 
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membrane of the endothelial cells (facing the lumen of blood vessels) and prevent entry of 
xenobiotics from the systemic circulation into the neural retina. Like in the outer BRB, tight 
junction proteins expressed on the inner BRB also severely limits paracellular diffusion of 
hydrophilic compounds. The barrier properties of the retinal blood vessel endothelial cells are 
commonly referred to as the inner BRB. Additionally, because of extensive intestinal and heapatic 
metabolism, the hydrophilic metabolites of the phytochemicals are seen in the systemic circulation 
and are available for penetration into the ocular tissues. The ambiguity in the results obtained from 
the limited number of clinical studies that have been carried out with the phytochemicals could be 
because of the inadequate delivery of the compounds into the tissues of the eye [75]. 
  Periocularly administered agents also encounter the RPE barrier. Thus, the inner and outer 
BRB acts as a considerable physiological barrier to the ocular delivery of therapeutic agents 
through the systemic and transcleral routes of administration. Additionally, transcleral permeation 
is also challenged by the scleral and choroidal blood flow and lymphatics.  
  Intravitreal and surgical interventions, though very effective, are associated with risks such 
as retinal detachment and endophthalmitis [76]. Topical administration is the most favored route 
of administration for ocular disorders. It is thought that following topical application diffusion into 
the cornea, followed by lateral migration into the sclera and then diffusion across the choroid and 
RPE into the vitreous, is the major pathway for topically administered agents [77]. Thus, scleral 
and choroidal vascular and lymphatic systems as well as the RPE present significant barriers in 
the diffusional path. Additionally, precorneal loss, corneal ultrastructure and efflux proteins 
expressed on the corneal membrane present additional physiological barriers to topically 
administered agents. Although significant advances have been made with respect to drug delivery 
into the front of the eye through the topical route, back-of the eye delivery remains a significant 
11 
 
challenge. Thus there is a necessity in development of novel noninvasive sustained release drug 
delivery strategies. 
The goal of this project is to develop novel formulations of Hesperetin (HT), 
Tetrahydrocannabinol valine hemisuccinate (THC-Val-HS) and Diclofenac sodium (DFS) and to 
evaluate in vivo ocular distribution and pharmacodynamic response through the non-invasive 
topical route. Melt-cast films and colloidal systems will be evaluated with respect to ocular 
distribution and pharmacodynamic response in vivo.  
1.3. Specific aims: 
1. Develop melt-cast films and solid lipid nanoparticles (SLN’s) of Hesperetin (HT) and 
evaluate in vivo ocular distribution in male New Zealand albino rabbits. 
2. Evaluate intraocular pressure lowering (IOP) efficacy of tetrahydrocannabinol (THC) and 
THC-Val-HS and compare with marketed formulations in a glaucoma induced rabbit 
model. 
3. Evaluation of the effect of cyclodextrins on morphology and barrier characteristics of 
isolated rabbit corneas. 
4. Development and evaluation of sustained release DFS ion exchange resin complexes 
loaded into melt cast films and their in vivo ocular distribution. 
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CHAPTER 2 
 
INTRODUCTION 
Bioflavonoids, a group of plant polyphenols, are reported to exhibit antioxidant, anti-
angiogenic and anti-inflammatory properties along with fluid retention reduction and capillary 
wall strengthening activities [78, 79]. Hesperidin (HD), and its aglycone hesperetin (HT), a plant 
based flavanone (Fig. 2.1A & 2.1B) obtained from Citrus sinensis, possess antioxidant [80, 81], 
and neuroprotectant properties [80], and reduces vascular permeability. HT is recognized to be 
more potent than HD in scavenging reactive oxidative species (ROS) [82-84]. HT also prevents 
the cytotoxic effect of peroxynitrites by converting them to non-toxic mono-nitrated products and 
increasing phosphorylation of extracellular-signal-regulated kinases (ERKs) [85]. Anti-
inflammatory activity of HT is thought to be achieved by inhibition of the COX-2 pathway and 
synthesis of PGE2 [86], and inhibition of nitric oxide production by blocking nitric oxide synthase 
[87, 88].  Additionally, HT was observed to increase ocular blood flow and promote recovery of 
retinal function following ischemic insult of retina [89]. Currently HT is available as an oral dietary 
supplement to improve blood flow and as a vasoprotectant. Cumulative urinary recovery of HT 
suggests a bioavailability of less than 25 % after oral administration of HD and HT [90]. Poor oral 
bioavailability of HT can be attributed to its rapid metabolism into hydrophilic glucuronide 
metabolites [91] and short half-life (Plasma half-life: 6.7 h and vitreous humor half-life: 110 min) 
[92, 93].  
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Treating the posterior segment eye diseases has always been a great challenge because of 
the unique physiological and anatomical barriers of the eye. Our earlier studies demonstrate that 
systemic application fails to deliver HT to the ocular tissues [91]. This makes topical or 
intraocular/periocular application the most effective. Less than 5 -10 % of topically applied drug, 
however, permeates into the intraocular tissues [94-96]. Various ocular delivery systems are being 
investigated to increase drug contact time and site specific delivery to the posterior segment of the 
eye using liposomal formulations and other sustained release and controlled release systems such 
as ocular inserts, collagen shields, matrix systems, and hydrogel lenses [97-100].  
The goal of the present study is to evaluate the effectiveness of topical melt-cast polymeric 
matrix systems and solid lipid nanoparticles with respect to the delivery of HT to the back-of-the-
eye tissues, especially to the retina-choroid (RC) and vitreous humor (VH). The matrix film and 
the SLN’s were evaluated in vivo for dose dependent and time dependent drug delivery in 
anesthetized and conscious animal model.   
2.2. Methods:  
2.2.1. Chemicals: 
PEO (PubChem CID: 5327147) [PolyOx® WSR N-10 (PEO N-10), MW: 100,000 
Daltons] was kindly donated by Dow Chemical Company (Midland, MI). HT (PubChem CID: 
72281) (Type HP-2, from Helix pomatia) was purchased from Sigma Aldrich (St. Louis, MO). 
Geleol™ Mono and Diglycerides NF (GMS: PubChem CID: 24699) and Compritol® 888 ATO 
(PubChem CID: 5362585) were gifted by Gattefossé. All other chemicals were purchased from 
Fisher Scientific (St. Louis, MO). 
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2.2.2. Animal tissues: 
Whole eye globes of New Zealand albino rabbits were purchased from Pel-Freez 
Biologicals® (Rogers, AK), shipped overnight in Hanks Balanced Salt Solution (HBSS) over wet 
ice [32]. Corneas and whole eye globes were used on the day of receipt. 
2.2.3. Animals: 
Male New Zealand albino rabbits (2.0 - 2.5 Kg) procured from Harlan Laboratories® 
(Indianapolis, IN) were used in all the studies. All animal experiments conformed to the tenets of 
the Association for Research in Vision and Ophthalmology statement on the Use of Animals in 
Ophthalmic and Vision Research and followed the University of Mississippi Institutional Animal 
Care and Use committee approved protocols (UM protocol # 11-006 and 14-002). 
2.2.4. Formulations:  
2.2.4.a. Preparation of polymeric matrix film: 
Melt-cast method was employed in the preparation of the polymeric matrix film (Fig 2.2). 
PEO N10 was selected as the matrix forming polymer. A physical mixture of HT and PEO N10 
was prepared by geometric dilution. Drug load in the film was 10 % or 20 % of the total weight of 
film. A 13 mm die was placed over a brass plate and heated to 70 °C using a hot plate. The physical 
mixture of HT and polymer was added in the center of the die and compressed to form a flat matrix 
surface. The mixture was further heated for 2-3 min. After cooling, 4 mm x 2 mm sections each 
weighing approximately 8 mg and with a drug load of 0.8 mg or 1.6 mg for the 10 %w/w and 20 
%w/w films, respectively, were cut out from the film.  
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2.2.4.b. Preparation of Solid lipid nanoparticles:  
HT-SLNs were prepared using a hot homogenization method followed by probe sonication 
(Fig.2.3). Accurately weighed Compritol 888 ATO (60 mg) and Glyceryl monostereate (GMS: 
340 mg) was melted, and HT (5% w/w with respect to the lipid) was dissolved therein to obtain a 
clear lipid phase. Simultaneously, an aqueous phase, containing surfactants (Poloxamer 188 and/or 
Tween 80) and glycerin (2.25% w/v) in bidistilled water, was heated. The hot aqueous phase was 
then added to the melted lipid phase under stirring (magnetic stirrer) to form a premix (600 rpm, 
1–2 min). The premix was then subjected to emulsification at 16,000 rpm for 6 min using T 25 
digital Ultra-Turrax (IKA® Works, Inc.) to form a hot pre-emulsion. This pre-emulsion was further 
subjected to ultra-sonication using Sonics VibraCellTM at 15 sec pulse rate and 80% amplitude for 
5 min. The hot emulsion thus obtained was slowly cooled to room temperature to form HT-SLNs. 
Figure 2.2: Preparation of 10% and 20% w/w HT-Film using melt-cast technology. 
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The final concentrations of the lipid and HT in the formulation were kept constant at 4% w/v and 
0.1% w/v, respectively. 
 
2.2.4.c. HT-Cyclodextrin solution (1% w/v): 
Hesperetin cyclodextrin (CD) solution (1% w/v) for topical instillation was prepared by 
dissolving accurately weighed amount of HT in 100 µL of 1N sodium hydroxide and adding this 
solution to 10% HPβCD (prepared in IPBS, pH 7.4, containing 0.1% HPMC). Final pH was 
adjusted to 7.4 using 1N hydrochloric acid. 
2.2.5. Physicochemical characterization of the HT-Film and HT-SLN’s: 
To determine HT content, the film was placed in a mixture of methanol and dimethyl 
sulfoxide (DMSO) 50:50 and sonicated for 15 min until the film was completely dissolved in the 
solvent mixture. Content uniformity was determined using four separate sections of 8 mg each, 
Figure 2.3: Preparation of HT-SLN’s using hot homogenization method followed by Ultra-probe 
sonication. 
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randomly cut from a single 13 mm film and analyzed as described under analytical procedure using 
an HPLC-UV method [101]. 
The lipid in the HT-SLN dispersion was precipitated using 190-proof alcohol, and the drug 
content in the supernatant after centrifugation (13,000 rpm for 20min), as such or after further 
dilution with 190-proof alcohol, was measured using an HPLC system. 
The percentage of HT entrapped in the SLNs (% EE) was determined by measuring the 
concentration of free drug in the aqueous phase of an undiluted IN-SLN dispersion. The EE was 
evaluated by an ultrafiltration technique with a 100-kDa centrifugal filter device composed of a 
regenerated cellulose membrane (Amicon Ultra). An aliquot (500 mL) of undiluted HT-SLN was 
added to the sample reservoir and centrifuged at 5,000 rpm for 10 min. The filtrate obtained was 
further diluted with alcohol (190 proof) and analyzed for drug content using HPLC.  
The mean particle size and the polydispersity index (PI) of HT-SLN’s were determined by 
photon correlation spectroscopy using Zetasizer Nano ZS Zen3600 (Malvern Instruments, Inc.) at 
25 oC and 173o backscatter detection in disposable folded capillary clear cells. The measurements 
were obtained using a helium-neon laser of 633 nm, and the particle size analysis data were 
evaluated using volume distribution. Zeta-potential measurements were carried out at 25 oC in 
folded capillary cells using the same instrument. For measurement of particle size distribution and 
zeta-potential, SLN samples were diluted (1:500) with water. All measurements were performed 
in triplicates. 
2.2.6. Differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy 
(FTIR): 
DSC thermograms for HT, excipients, the 10 %w/w film and 0.1% HT-SLN’s was 
collected using a Diamond Differential Scanning Calorimeter (Perkin-Elmer® Life and Analytical 
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Sciences) [102].The samples were weighed and sealed in aluminum pans and were heated from 0 
oC to 270 oC at a heating rate of 10 oC/min under nitrogen purge (20 mL/min). 
Infrared spectra (IR) for excipients used in both formulations, HT, and the final 
formulations were obtained using a Cary 660 series FTIR (Agilent Technologies) and MIRacle™ 
Single Reflection ATR (PIKE Technologies). Further, the IR spectrum of the 13 mm matrix film 
was collected randomly from different areas of the film, to evaluate distribution uniformity within 
the polymer matrix.  
2.2.7. In vitro release and corneal permeability studies: 
2.2.7.a. HT-Film: 
To study the release profile of HT from the film, in vitro release studies were carried out 
as depicted in figure 2.4. Three 20 mL glass vials were taken and a 10 %w/w film (8 mg; Dose: 
0.8 mg) was placed at the bottom of each vial. A standard US 100 mesh sieve was placed over the 
film and a magnetic bead was placed on the sieve. The glass vials were placed over a magnetic 
stirrer. Similar set up was employed in 3 more vials but without the sieve and the magnetic stirrer 
Figure 2.4: Release of HT from film using standard US 100 mesh sieve and without 
sieve. 
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to evaluate the barrier characteristics of the sieve, if any. In both cases, 18 mL of 5 %w/v HPβCD 
was used as the release/dissolution medium to ensure sink conditions were maintained (0.6 mg of 
HT is soluble in 1 mL of 5 %w/v HPβCD). The temperature was maintained at 34 ± 2 oC using hot 
plates. Aliquots, 0.8 mL, were collected at specific time intervals and replaced with an equal 
volume of release medium. The release studies were carried out for a period of 2 h. Samples were 
analyzed using a HPLC-UV method [101].  
In vitro corneal permeability of HT from the matrix film was evaluated using a side-by-
side diffusion apparatus (PermeGear, Inc., Hellertown, PA) for 3 h (Fig. 2.5). The studies were 
carried out by sandwiching the film (4 mm x 2 mm; 10 %w/w HT; weighing 8 mg approximately; 
0.8 mg HT) in between a Spectra/Por® membrane (MWCO: 10,000 Daltons) and isolated rabbit 
cornea (Pel-Freez Biologicals; Rogers, AK). Corneas were excised from whole eye globes, 
following previously published protocols [103], with approximately 1 mm scleral portions 
remaining for ease of mounting. The membrane-film-cornea sandwich was then placed in between 
Figure 2.5:  Side-by-side diffusion apparatus setup used for in vitro 
release and transcorneal permeability studies. 
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the side-by-side diffusion cells (the chamber towards the Spectra/Por® membrane representing the 
periocular surface and the chamber towards the cornea representing the aqueous humor) and 
samples were collected and analyzed as described above under release study. The side-by-side 
diffusion cells maintained at 34 °C using a circulating water bath. Five percent HPβCD in isotonic 
phosphate buffer saline (IPBS) (pH 7.4) was used as the receiver medium. Aliquots (0.6 mL) were 
drawn at every 30 min interval and replaced with an equal volume of fresh buffer. Samples were 
analyzed by a HPLC-UV method [101].  
2.2.7.b. HT-SLN’s: 
To determine percentage release and transcorneal permeability of HT from the SLN’s, side-
by-side diffusion apparatus (PermeGear, Inc., Hellertown, PA), Spectra/Por® membrane and 
isolated rabbit cornea were used for the release and permeability studies respectively. Three mL 
of HT-SLN’s 0.1% w/v were filled in the donor chamber and 3.2 mL of 5%w/v RMβCD was used 
as receiver solution. Aliquots of 0.6 mL were collected at predetermined time points and replaced 
with fresh media. Samples were analyzed using HPLC-UV method. 
 2.2.8. Ex vivo studies: 
 Whole eye globes obtained from Pel-Freez were placed in 12 well tissue culture plates 
containing IPBS (pH 7.4) with corneas facing upwards. IPBS was added to the wells and was 
maintained below the level of corneo-scleral-limbus. The whole set up was maintained at 34 oC 
using a water bath. The 10 %w/w HT film was placed at the corneo-scleral-limbus and the eye 
globes were allowed to stand for 3 h. At the end of 3 h the surface of the eye globes were washed 
thoroughly and aqueous humor (AH), vitreous humor (VH) and retina-choroid (RC) were carefully 
isolated and analyzed for HT content using HPLC-UV method [101]. 
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2.2.9. In vivo bioavailability studies: 
Male New Zealand albino rabbits weighing between 2.0 - 2.5 Kg were used to determine 
in vivo bioavailability of HT from the matrix film and SLN’s in a time and dose dependent manner. 
Initially ocular distribution studies were conducted in anesthetized rabbit model. For this study 
rabbits were anesthetized using a combination of ketamine (35 mg/kg) and xylazine (3.5 mg/kg) 
injected intramuscularly, and maintained under anesthesia throughout the experiment. In these 
studies, either the 10 % or the 20 %w/w HT loaded films were placed in the conjunctival sacs of 
the rabbit eye. Similarly, 100 µL of HT-SLN’s 0.1% w/v were administered in the cul-de-sac of 
the rabbit eye.  
To evaluate the effect of active lymphatic and tear drainage on the ocular distribution of 
HT, studies were conducted in the conscious animal model also. HT-CD solution was used as 
control formulation for these studies.  
At the end of each study, rabbits were euthanized under deep anesthesia with an overdose 
of pentobarbital injected through the marginal ear vein. The eyes were washed with ice cold IPBS 
and immediately enucleated and washed again. Ocular tissues were separated, weighed and 
preserved at -80 °C until further analysis using HPLC-UV method [101]. All experiments were 
carried out in triplicate. Corneal tissues following 6 h time point were evaluated for morphological 
changes, if any. Corneas from the contra-lateral eye of the animal were used as controls. 
2.2.10. Corneal histology 
Corneas exposed to the 20 %w/w HT film (highest dose tested) for 6h (longest duration) 
in vivo were collected and evaluated for histological characteristics. Corneas excised from the 
contralateral eyes were used as controls. Extracted corneas were fixed in 2 %w/v 
paraformaldehyde and 2 %v/v gluteraldehyde in IPBS. Histological evaluation was carried out at 
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Excalibur Pathology Inc. (Oklahoma City, OK) as per previously reported protocols [104]. 
Corneas embedded in paraffin were sliced into 5µm cross sections using a microtome (American 
Optical® 820 Rotary Microtome). These sections were placed on a slide and dried overnight in an 
oven at 68 oC. The slide was washed with xylene to remove paraffin and washed with alcohol and 
water to hydrate the tissue. This was then stained with nuclear dye Gill III hematoxylin (StatLab 
medical) for 10 min and rinsed, and then counterstained with eosin. These slides were then washed 
in reverse manner (running water, alcohol, and xylene), cover slipped and examined under 
microscope (Chromavision ACIS II). 
2.2.11. Analytical procedure for in vitro Samples 
Waters HPLC system with 600 E pump controller, 717 plus auto sampler and 2487 UV 
detector was used. Data handling was carried out using an Agilent 3395 integrator. HT stock 
solution was prepared in acetonitrile (ACN). A 50:50 mixture of 20 mM phosphate buffer (pH 2.5) 
and ACN was used as mobile phase with Phenomenex Luna® 5 µm C18 100 Å, 250 x 4.6 mm 
column at a flow rate of 1 mL/min and 284 nm. 
2.2.12. Bio-analytical method 
2.2.12.a. Standard solution preparation: 
To 100 µL of aqueous humor (AH) or 500 µL of vitreous humor (VH) and to a weighed 
amount of the cornea, sclera, iris ciliary bodies (IC) and retina-choroid (RC), 20 µL of HT stock 
solution in ACN (0.5, 1, 2.5, 5, 7.5, and 10 µg/mL) was added and allowed to stand for 5 min. To 
precipitate the proteins, ice cold ACN was added to the AH and VH standards in 1:1 ratio and 1 
mL to the cornea, sclera, IC and RC standards. Final concentrations of the standard solutions 
prepared were in the range of 10 - 200 ng/mL for AH; 10 - 100 ng/mL for VH; 20 - 200 ng/mL: 
cornea & sclera and 10 - 200 ng/mL: IC & RC. All samples were centrifuged at 13,000 rpm and 4 
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oC for 30 min and analyzed using HPLC-UV. All the standard curves generated an R2 value greater 
than 0.95. Average recovery values were determined in AH (93.5 %), VH (94.7 %), IC (92.1 %), 
RC (97.3 %), cornea (89.6 %) and sclera (88.7 %).  
2.2.12.b. Sample preparation: 
Approximately 0.1 mL of AH and 0.5 mL of VH was collected from each test eye into 
individual centrifugal tubes. All other tissues, RC, IC, cornea & sclera, from each test eye were 
individually cut into very small pieces and placed into individual vials. Protein precipitation was 
carried out similar to the standard solution preparation and analyzed using HPLC-UV method. 
A mixture of 20 mM phosphate buffer (pH 2.5) and ACN in a ratio of 65:35 was used as the mobile 
phase and Phenomenex Luna® 5 µm C18 100 Å, 250 x 4.6 mm column at a flow rate of 1 mL/min 
and 284 nm.  
2.2.13. Data analysis 
All experiments were carried out at least in triplicate.  
The entrapment efficiency (EE) of HT in the SLN’s was estimated using Equation (1): 
EE (%) = [(Wi -Wf)/(Wi)] X 100 
Where,  
Wi = total drug content,  
Wf = amount of free drug in aqueous phase. 
HT release data was fitted to zero order, first order and Higuchi models (Equations 2, 3 & 4). 
Ct = C0 + K0t 
LogCt = LogC0 + Kt/2.303 
Ct = KHt1/2 
Where, 
Eq (2) 
Eq (3) 
Eq (4) 
Eq (1) 
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 C0 & Ct = concentration at time 0 min and t min, 
 K0, K & KH = kinetic constants for zero order, first order and Higuchi models. 
Drug diffusion parameters across cornea such as cumulative amount (Mn) , rate (R) and 
flux (J) were calculated using previously described method [105].  
Cumulative amount of HT released from the film was calculated using equation 5 
 
 
Where, 
 n = sampling time point (n=1, 2, 3 and 4… corresponding to 15, 30, 45 and 60..min 
respectively), 
Vr = volume of the medium in the receiver chamber (mL),  
VS = volume of the sample withdrawn at the nth time point (mL),  
Cr(n) = concentration of the drug in the receiver chamber medium at nth time point (µg/mL). 
Steady state flux was determined using equation 6 
  
 Where, 
 M = cumulative amount of HT (µg), 
 t = time (min), 
 A= surface area of cornea (0.636 cm2). 
Statistical analysis was carried out using ANOVA to compare between different groups 
and Tukey’s post-hoc HSD was used to compare differences between two groups. A ‘p’ value less 
than 0.05 was considered to denote statistically significant difference. 
 
Mn= Vr Cr(n) +  Σ 
x=n 
x=1 
Vs(x-1) Cr(x-1) Eq (5) 
Flux (J) = (dM/dt) 
A 
Eq (6) 
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2.3. Results: 
2.3.1. Physicochemical characterization: 
HT content in all the films was observed to be approximately between 90 – 93 %  of the 
theoretical values and was found to be uniformly distributed within the matrix (RSD<2.3 %).  
HT content in the SLN’s was found to be 92 - 97% of the theoretical value. Entrapment efficiency, 
particle size, polydispersity index and zeta potential were found to be 86.4 ±0.7 %, 225.5 ± 21 nm, 
0.379 and -21 ± 9 mV respectively. 
2.3.2. DSC and FTIR studies:  
2.3.2.a. HT-Film: 
DSC thermograms of PEO N10, drug and polymeric film are presented in Figure 2.6. HT 
exhibited an endotherm at 234 oC corresponding to its melting point. PEO N10 exhibited a melting 
point temperature of 65 oC. PEO N10 demonstrated an endothermic peak shift from 65 to 63 and 
60 oC with the 10 %w/w and 20 %w/w films, respectively. HT peak at 245 oC was absent in the 
melt-cast films. 
  FTIR spectra of HT showed aromatic stretching from 1650 to 1500 cm-1, and –OH phenolic 
stretching was observed at 1200 cm-1. PEO revealed -CH stretching at 2890 cm-1. Scissoring and 
wagging movement of -CH2 were observed at 1450 and 1350 cm-1. Aromatic stretch bands 
corresponding to HT and -CH stretch bands corresponding to PEO N10 were observed with the 10 
%w/w film. Similar spectral bands were observed with the 20 %w/w film (Figure 2.7).  
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Figure 2.6: Differential scanning calorimetry thermograms of hesperetin (HT) polymeric 
matrix film, PEO N10 and HT. 
Figure 2.7: FTIR spectral images of PEO N10, hesperetin (HT), 10 %w/w HT polymeric 
matrix film and 20 %w/w HT polymeric matrix film. 
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2.3.2.b. HT-SLN: 
DSC thermograms of HT, GMS, Compritol 888 ATO, lyophilized HT-SLNs, and other 
excipients used in the formulation are presented in Figure 2.8. HT had similar endothermic peak 
at 234 oC as seen in the thermograms with the matrix film. All other excipients had corresponding 
endothermic peaks between 45 and 60 oC. The thermal curve of the bulk Compritol 888 ATO and 
GMS exhibited an endothermic peak at 70-75 oC. Additionally, an endotherm at 50-55 oC 
corresponding to the melting point of Pluronic F68 was also observed in HT-SLNs. The 
endothermic peak of HT was not observed in the SLN formulation. 
Figure 2.8: DSC thermograms of A) Compritol® ATO 888, B) GMS, C) Pluronic® F-68, D) 
HT and E) HT-SLN’s. 
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FTIR spectra of  IR spectra of compritol and GMS show typical bands at 2820 cm–1, due to C-H 
stretching, and 1705 cm–1 due to C = O (carbonyl) stretching (Fig.2.9). Pluronic F68 exhibits 
characteristic peaks at 2886 and 1112 cm−1 due to stretching vibrations of C–H, and C–O groups. 
Tween 80 exhibits broad peak between 3400 and 3600 corresponding to OH stercthing. While the 
peak at 2880 corresponds to CH stretching. The spectral peak corresponding to OH group in HT 
was absent in the SLN formulation. Instead a broad peak was observed.  
2.3.3. In vitro release and corneal permeability studies: 
Release of HT from the matrix films was 95.3 ± 1.3 % (with sieve) and 89.3 ±11.9 (without 
sieve and no stirring) within 120 minutes (Fig.2.10).  Rate and flux across the corneal and 
Spectra/Por® membranes were found to be 0.37 ± 0.03 μg/min and 0.58 ± 0.05 μg/min/cm2 and 
0.57 ± 0.05 μg/min and 0.89 ± 0.06 μg/min/cm2, respectively (Fig.2.11). Under the settings 
employed release towards the periocular surface (representing the precorneal loss) of HT from the 
film was found to be 16.1 ± 4.5 % in 3 h. Cumulative precorneal loss of HT was 1.7-folds higher 
HT-SLN's 0.1 %w/v
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Figure 2.9: FTIR spectra of HT-SLN’s and different excipients used in the preparation 
of HT-SLN’s. 
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than that observed across the cornea. Cumulative amount of HT permeating across the isolated 
rabbit cornea in 3 h was determined to be 59.9 ± 5.2 µg.  
 
HT release from the SLN’s was found to be 60.7 ± 6.03% in 3 h. Rate, flux and permeability 
coefficient of HT from the SLN’s were found to be 1.4 ± 0.2 µg/min, 2.2 ± 0.24 µg/min/cm2 and 
28.7 ± 3.1 x 10-6 cm/sec respectively. 
2.3.4. Ex vivo studies: 
HT content in the AH, VH and RC were found to be 5.8 ± 0.2 μg/gm of tissue, 5.6 ± 1.4 
μg/gm of tissue, and 14.2 ± 3.8 μg/gm of tissue, respectively. Amount of HT in RC was found to 
be 2.5-fold higher compared to that in the AH or VH.  
2.3.5. In vivo studies: 
Initially, ocular tissue concentrations obtained with 10 %w/w HT loaded matrix film was 
evaluated in vivo 1h after topical application of the film in anesthetized animal model. AH, VH, 
IC, RC, cornea and sclera were analyzed for HT content. Significant levels of HT were detected 
in the IC, cornea and sclera tissues. HT levels were also observed in the back-of-the-eye tissues: 
Figure 2.11:  In vitro transcorneal 
permeability of HT from 10 %w/w matrix 
film across isolated rabbit cornea. 
Figure 2.10: Percentage release of HT from 
10 %w/w film across the standard US 100 
mesh and without sieve. 
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VH (0.05 ± 0.03 μg/gm of tissue) and RC (7.8 ± 0.2 μg/gm of tissue). When, HT load in the film 
was doubled (Dose: 1.6 mg per 4 mm x 2 mm; 8 mg of film) HT levels in the AH, IC, and cornea 
were 2-fold higher than that of the 10 %w/w HT film. With the 20 %w/w film, amount of HT in 
the posterior segment ocular tissues was found to be 1.4 ± 0.5 μg/gm of tissue (VH) and 23.5 ± 6.9 
μg/gm of tissue (RC). It was observed that doubling the dose of HT in the matrix resulted in an 
approximately 10- and 28-folds increase in scleral and VH HT concentrations, respectively. The 
results are presented in Figure 2.12 A&B.  
Ocular tissue concentrations, 3 h post topical instillation of the 10 %w/w and the 20 %w/w 
HT film in vivo, were also evaluated. Expectedly, HT concentrations at the end of 3h were 
relatively low compared to the 1 h time point. Results from the 3 h study are presented in Figure 
2.12 A&B.  
Figure 2.12 A: Ocular tissue hesperetin (HT) concentrations (µg/g of tissue) 
obtained from 10%w/w film 1h and 3h following topical application. * - 
Significantly different from 10%w/w HT-3 h. Anesthetized animal model. 
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Ocular tissue HT concentrations obtained with the 20 %w/w film was also tested 6 h post 
topical application. HT was detected in VH (0.03 ± 0.02 μg/gm of tissue), RC (0.4 ± 0.02 μg/gm 
of tissue), IC (1.5 ± 0.1 μg/gm of tissue) and sclera (6.1 ± 1.6 μg/gm of tissue) (Figure 2.8 B). Only 
the posterior segment ocular tissue concentrations were determined in the 6h study as the cornea 
was carefully isolated and taken for histology studies. Thus, both cornea and AH HT 
concentrations were not determined in the 6h study. 
Ocular distribution of HT from the SLN’s are presented in figure 2.13. Anterior chamber 
of the eye exhibited high HT levels with the HT-SLN’s 1 h post topical application. While the 
posterior segment of the eye had very little concentration of HT.  
 
Figure 2.12 B: Ocular tissue hesperetin (HT) concentrations (µg/g of tissue) 
obtained from 20%w/w film 1h, 3h and 6h following topical application. ND – not 
determined. Ψ - Significantly different from 10%w/w HT-3h and 6h, ḉ - 
Significantly different from 10%w/w HT- 1h and 6h and ḙ- Significantly different 
from 10%w/w HT- 1h and 3h. Anesthetized animal model. 
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Ocular distribution of HT in the conscious animal model with active lymphatic and tear drainage, 
HT-Film, HT-SLN’s and HT-CD solution were evaluated after 3 h of topical application. Results 
were presented in the figure 2.14.  
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application. ND – below detection limit. AH-aqueous humor, IC-Iris ciliary bodies, VH-
Vitreous humor and RC-Retina choroid. Conscious animal model.  
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Table 2.1: Compiled ocular tissue hesperetin (HT) concentrations (µg/g of tissue) obtained from 
1% w/v HT+10% w/v HPβCD, 10% w/w and 20%w/w film and 0.1% HT-SLN’s at the end of 1h, 
3h, and 6h following topical application. ND – below detection limit. AH-aqueous humor, IC-Iris 
ciliary bodies, VH-Vitreous humor and RC-Retina choroid. A-Anesthetized animal model and C-
Conscious animal model. 
Formulatio
ns 
Volume; Dose 
(mg) 
Time 
(h) 
Mode
l 
Tissue concentrations (µg/gm of tissue) 
Corne
a AH IC VH RC 
Scler
a 
Solution 
(1 % w/v 
HPβCD) 
100 µL; 1 mg 3 C 3.5 ± 0.5 
0.08 ± 
0.05 
1.8 ± 
0.1 
0.02 
± 
0.01 
0.52 
± 0.1 
5.4 ± 
1.2 
Film (10% 
w/w) 
4 mm x 2 mm 
x 0.2 mm; 0.8 
mg 
1 A 14.1 ± 0.2 
4.2 ± 
0.4 
37.6 
± 6.2 
0.05 
± 
0.03 
7.8 ± 
0.2 
5.02 
± 0.9 
Film (10% 
w/w) 
4 mm x 2 mm 
x 0.2 mm; 0.8 
mg 
3 A 8.5±0.9 
1.2±0.
1 
4.2±
1.1 
0.06
±0.0
2 
1.8±0
.5 
14.6
±8.8 
Film (20% 
w/w) 
4 mm x 2 mm 
x 0.2 mm; 1.6 
mg 
1 A 33.5 ± 5.4 
7.2 ± 
3.6 
44.9 
± 
19.7 
1.4 ± 
0.51 
23.5 
± 6.9 
53.2 
± 5.2 
Film (20% 
w/w) 
4 mm x 2 mm 
x 0.2 mm; 1.6 
mg 
3 A 14±1.1 
3.4±0.
9 
7.7±
0.8 
0.16
±0.0
7 
3.3±0
.4 
39.8
±16.
1 
Film (20% 
w/w) 
4 mm x 2 mm 
x 0.2 mm; 1.6 
mg 
3 C 4.1 ± 0.4 
0.03 ± 
0.01 
3.01 
± 0.4 
0.08 
± 
0.03 
2.3 ± 
0.96 
15.5 
± 5.7 
Film (20% 
w/w) 
4 mm x 2 mm 
x 0.2 mm; 1.6 
mg 
6 A NA NA 1.5±.1 
0.03
±0.0
2 
0.38±
0.02 
6.1±
1.6 
SLN 
(0.1% 
w/v) 
100 µL; 0.1 
mg 1 A 
16.4 ± 
5.2 
2.6 ± 
0.1 
15.2 
± 0.2 
0.03 
± 
0.01 
0.59 
± 
0.02 
1.6 ± 
0.6 
SLN 
(0.1% 
w/v) 
100 µL; 0.1 
mg 3 C 
1.7 ± 
0.7 
0.01 ± 
0.001 
1.9 ± 
0.36 ND ND 
0.9 ± 
0.2 
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Corneas exposed to the 20 %w/w HT film for 6 h did not show any substantial damage 
when compared to the control. Extracellular swelling of the corneal epithelium or stromal lamellae 
was observed in the control and the corneas exposed to the film representing the minor artifacts 
that were introduced during the fixating process (Fig. 2.15).  
2.4. Discussion: 
In this study HT was incorporated into a polymeric matrix system utilizing a melt-cast 
method. In this method, the active compound is embedded in a carrier matrix comprised of one or 
more meltable substances and other functional excipients. Once the formulation comes into contact 
with the release media (in vitro) or tear fluid (in vivo) it quickly transforms into a gel and releases 
the drug slowly over prolonged periods of time, depending on the matrix composition. Moreover, 
high drug loads (20 - 40 %w/w) can be easily incorporated without the need for any organic 
solvent. Importantly, both hydrophilic and hydrophobic moieties can be incorporated into the 
polymeric matrix without any difficulty. Considering the low volumes that can be administered 
Figure 2.15: Histological images of rabbit corneas exposed to 1) IPBS & 2) 20 %w/w 
HT film for 6h. 
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topically (35 - 50 µL in general) and the fact that a large number of new drug candidates are poorly 
water soluble, most of the current dosage forms require surfactants or other solubilization 
approaches. The melt-cast technology converts the compounds into its amorphous state, or 
disperses them at a molecular level in the polymer matrix, because of which the solubility of the 
compound is increased. Increased solubility could improve transcorneal permeability of the 
therapeutic agent several folds. By altering the type of matrix polymer, this process technology 
can be employed to design sustained release dosage forms.  
In this study we also evaluated solid lipid nanoparticles (SLN’s) as a secondary approach 
to deliver HT to the intraocular tissues. Nanotechnology offers many advantages in drug delivery 
from controlled release to targeted drug delivery.  SLNs have been used in the field of ocular drug 
delivery for decades. They have shown enhanced corneal absorption and improved ocular 
bioavailability of both hydrophilic and hydrophobic drugs. In this study, we have prepared HT-
SLN using a mixture of 15% Compritol and 85% GMS. Particle size of HT-SLN’s was 225 nm 
approximately. This helps improve corneal absorption and at the same time keeps them from 
getting eliminated easily from the ocular surface and tissues. With Zeta potential at -21 mV, a 
stable SLN’s were achieved. Although the polydispersity index of the SLN’s was slightly higher 
than the ideal requirement (approximately ≤0.2), further optimization of the process technique can 
be helpful. 
We prepared the melt cast films with 10 %w/w and 20 %w/w HT loads such that the total 
amount of HT per unit dosage of 4 mm x 2 mm film was maintained at 0.8 mg and 1.6 mg, 
respectively. The thickness of the films was maintained between 0.2 mm - 0.4 mm. PEO N10 was 
selected as the matrix forming material because of its good aqueous solubility, low viscosity and 
low toxicity [106]. Since the polymer is water soluble, it can easily transform into a gel and be 
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slowly washed away by the tear fluid. PEO N10 has a low melting point and an excellent film 
forming ability. This property helps in achieving smooth flexible films at low temperatures and 
can thus be employed to develop matrix films for thermo-sensitive compounds. Surface of the film 
was flat and smooth avoiding any discomfort in vivo. Uniform distribution of HT was achieved 
within the polymeric matrix by continuous geometric dilution as confirmed by both FTIR and 
HPLC analysis. PEO N10 has been reported to form simple binary eutectic mixtures due to its low 
entropy of fusion thereby improving drug release from the matrix [107, 108]. Endothermic peak 
shifts observed in the DSC thermograms could be because of this eutectic mixture formation. 
Side-by-side diffusion apparatus was employed to determine flux across the cornea. A 
modified protocol was used to represent periocular loss of HT from the film. To the best of our 
knowledge, this is the first time an in vitro model has been used to study transcorneal permeation 
in the presence of precorneal/periocular loss. In this study, flux across the Spectra/Por® membrane, 
used on the precorneal side, was 1.7-fold greater than the corneal tissue. The ratio of precorneal 
loss to corneal penetration was thus 1.7:1 under the conditions tested. By changing the 
experimental parameters (e.g. use of different backing membranes, vertical apparatus, sandwiched 
cassettes, continuous dilution of the donor chamber solution) periocular/precorneal loss can be 
increased to mimic precorneal loss in vivo and to develop in vitro in vivo correlations. The 
apparatus/set-up can be easily modified to accommodate various types of ophthalmic formulations.  
Release of HT from the film, with or without sieve, followed the Higuchi model with 
coefficient of determination (R2) 0.9899 and 0.9873, respectively. The results demonstrate that the 
sieve did not act as a barrier to HT release and diffusion in the release medium. Flux across the 
membranes exhibited zero-order kinetics. In vitro transcorneal flux was several folds greater than 
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that obtained with other formulations reported in the literature [109], even in the presence of a 
precorneal loss. This demonstrates the value of the melt-cast topical HT dosage form. 
The whole eye globes obtained from Pel-Freez Biologicals served as a good ex vivo model. 
HT film required approximately 30 min to transform into a gel in the absence of any tear fluid. 
The concentrations observed in the RC were 3-fold higher when compared to the levels in the AH 
and VH. The results suggest that the film was preferentially delivering HT to the posterior segment 
of eye through conjunctival-scleral pathway. Considering the data, from the subsequent in vivo 
studies, ocular tissue concentrations of HT in AH, VH and RPE were found to be overestimated 
in the ex vivo model due to lack of vascular and lymphatic drainage systems.  
As expected, and unlike the ex vivo studies, HT films transformed into a gel in less than 5 
min following topical application. This was much quicker when compared to the ex vivo study due 
to the presence of tear fluids. Allergic reactions such as inflammation or redness or excessive 
tearing were not observed throughout the duration of the study. Results from the topical HT films 
indicate that significant levels of HT can be delivered to the posterior segment of the eye with 
these matrix film formulations. With the 10 %w/w HT film significant amounts of HT was detected 
in both VH and RC. On doubling the amount of HT in the matrix, VH and RC levels markedly 
increased by 28- and 3-folds, respectively. Thus, a dose dependent concentration profile was 
observed from the matrix system. Significant HT levels were detected in the cornea, sclera, IC and 
AH 1 h post topical application of the matrix. The concentration profile, higher HT concentrations 
in the RC when compared to the VH, was consistent with scleral absorption pathway, as also 
suggested by the ex vivo studies. High drug concentration in the PEO matrix in close contact with 
the ocular tissues could favor direct partitioning from the matrix into the ocular tissues. This might 
40 
 
be one of the possible reasons for achieving significant intraocular tissue concentrations from the 
matrix film.  
With SLN’s, the dose administered was 8 and 16-folds lower than the 10% w/w and 20% 
w/w film. Even at such low doses HT-SLN’s were able to deliver significant levels to the anterior 
segment of the eye (Table 2.1). When compared with the solution formulation, which has a 10 fold 
higher dose than the SLN formulation, SLN’s were able to deliver much higher concentration to 
the anterior segment tissues. This shows improved ocular absorption of the nanoparticle through 
corneal route of absorption.  
Ramesh et al, have previously evaluated ocular bioavailability of HT through intravenous 
and topical routes of application [110]. In these studies, 1 %w/v HT solution (Dose: 1 mg) for 
topical instillation was prepared using 10 %w/v HPβCD and 10 %w/v RMβCD. HT concentrations 
in the AH, VH, RC and IC achieved with the 1 %w/v HT-CD solution (dose: 1 mg; 100 µL instilled 
volume) were approximately 3-5 folds lower than the levels obtained with the 10 %w/w HT film 
(Dose: 0.8 mg) in the current study. Concentrations in the sclera and cornea were similar in both 
the cases. When benzalkonium chloride (BAK) was included in the HT-CD solution formulation 
[110], the ocular tissue concentrations achieved were 2-fold higher than that obtained with the 10 
%w/w film, which did not contain any BAK, at the 1 h time point [110]. The 20 %w/w HT film, 
however, was able to deliver significantly higher HT levels in all cases. Thus, although the melt-
cast film did not have any preservatives or solubilizers, the intraocular tissue concentrations 
achieved with this dosage form were very high.  
HT is rapidly eliminated from the ocular tissues due to choroidal and lymphatic drainage. 
HT levels in all ocular tissues declined rapidly after application of both 10 % and 20 %w/w film 
(Fig.2.12A & B). Less than 50% of the concentration determined at the 1 h time point remained 
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in the VH, RC and IC 3 h post topical application, suggesting a vitreal half-life of less than 2 h. 
The results are consistent with vitreal half-life of 110 minutes reported in earlier studies [110]. 
Matrix films containing 20% HT, however, maintained significant levels in all the ocular tissues 
at the end of 3 h. In fact, with the 20 %w/v HT films a significant amount of HT was maintained 
in the VH and RC and other ocular tissues, even after 6 h post application.  
Smith et al. reported that at 0.1-0.3 µM (30.2 - 90.7 ng/mL) concentrations, HT 
demonstrates neuroprotective activity when mouse primary cortical neurons were subjected to a 
pro-apoptotic insult by exposing them to staurosporine [111]. All studies determining IC50 values 
report solution concentrations and not actual tissue concentrations. Thus, the AH and VH 
concentrations, which are in equilibrium with the anterior and posterior segment ocular tissues, 
serve as good therapeutic response indicators for IC and RC sites. Considering that the VH is on 
the receiving side with the scleral side being the dosing side (topical application) it can be expected 
that the HT concentrations in the RC or IC will be well within the therapeutic range at least for as 
long as the VH and AH concentrations are within the IC50 range. In the current study we observe 
that even at the 6h time point, the levels of HT in VH (30 ng/mL), are within this range. Although 
the AH was not analyzed at the 6h time point, since the AH concentrations were typically several 
folds greater than the VH concentrations at all time-points, following topical application, it can be 
concluded that the AH concentrations would also be within the neuroprotective concentration 
range at the 6h time point. Thus, with the 20% matrix films, ocular tissue HT concentrations were 
maintained within and above levels required for neuroprotectant activity for at least 6h post topical 
application.  
With respect to anti-oxidant activity, HT levels at the end of 1 h in the AH (4.2 µg/mL) 
was greater than the IC50 values for peroxynitrites (IC50: 4.67 µM; 1.4 µg/mL) and superoxide 
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inhibition (IC50: 7.47 µM; 2.3 µg/mL) [82]. With the 20 %w/w film, at the end of 1h, HT levels in 
both AH and VH were above these IC50 values. Levels of HT in AH (3.4 µg/mL) were maintained 
above the IC50 values for peroxynitrites and superoxide inhibition even at the end of 3h, following 
topical application of the 20 %w/w film. 
In terms of anti-inflammatory activity, Yang et al. reported that at 1-10 µM (0.3 – 3.02 
µg/mL) HT concentrations, cellular levels of COX-2 and PEG2 are markedly attenuated [112]. 
With both the 10% and 20 %w/w films, HT levels in the AH (1.2 and 3.4 µg/mL, respectively) 
were maintained within the concentration range required for COX-2 and PEG2 inhibition, even at 
the end of 3h. 
When the 1%w/v HT+10%w/v CD solution, 0.1%w/v HT-SLN’s and 20%w/w HT-Film 
formulations were tested for intraocular distribution in the conscious animal model, 3 h post topical 
application, HT concentrations in all the tissues dropped significantly compared to the anesthetized 
model. This was expected and can be attributed to the active lymphatic and tear drainage in 
conscious animals. Aqueous humor outflow is presumed to be the one of the major routes of 
elimination from the intra ocular tissues [113]. As a result, AH concentrations in all conscious 
animal model were significantly lower compared the same formulations in anesthetized model 
(Table 2.1). When these concentrations were compared against the IC50 values, films were able to 
maintain neuroprotective HT levels in all the tissues. Anti-oxidant and anti-inflammatory levels 
were maintained in IC and RC. Although SLN’s were administered at much lower doses, were 
able to deliver significant levels of HT to the anterior segment of the eye. But we were not able to 
achieve and maintain the levels in posterior segment of the eye.  
Thus, the polymeric matrix film was successfully able to deliver and maintain levels of HT 
required for neuroprotectant, anti-oxidant and anti-inflammatory activity in the ocular tissues. As 
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mentioned earlier, the AH and VH concentrations represent the innermost ocular tissues (receiver 
solutions) in the anterior and posterior segments, respectively, for a topical route of application. 
Thus, the concentrations in the retina, choroid, cornea or iris-ciliary bodies would be significantly 
higher compared to what would be achieved if the AH or VH concentrations were to represent 
donor concentrations (e.g. intravitreal injection). 
2.5. Conclusion: 
In conclusion, appreciable ocular tissue concentrations were achieved using non-invasive 
topical melt-cast films. A 2-fold increase in HT content in the matrix film led to several fold 
increase in the HT concentration in the ocular tissues. With the 20 %w/w HT film high 
concentrations of HT were maintained in the posterior segment ocular tissues even at 3 h post 
topical application. Quantifiable levels of HT was still retained in the VH and RC even after 6 h. 
While matrix films were able to deliver HT to the posterior and anterior segment of the eye, SLN’s 
can be a promising platform to deliver drug to the anterior segment of the eye. Corneal histology 
studies indicate that the formulations did not produce any damage to the ocular tissues. Thus, the 
melt-cast matrix films appear to be a promising approach for drug delivery to the back-of-the-eye.
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CHAPTER 3 
 
3.1. INTRODUCTION 
Glaucoma is an ocular neuropathy characterized by progressive and irreversible loss of 
vision. It affects nearly 60 million people worldwide and is the second leading cause of blindness 
[114]. Intraocular pressure (IOP) has been identified as an important risk factor in the pathogenesis 
of the disease [115]. Elevated IOP leads to damage to the retinal ganglion cell (RGC) axons leading 
to progressive and irreversible vision loss [116]. Current therapy targets a reduction in IOP to 
prevent progression of the disease. This, however, is often not enough to prevent or arrest the 
development of glaucoma related optic neuropathy [117-119]. A number of hypotheses exist, but 
the complete mechanism of RGC cell death has not yet been elucidated [120-122]. New classes of 
agents that can reduce IOP as well as prevent or slow the loss of RGC are direly needed.  
Δ9-Tetrahydrocannabinol (THC; Fig.3.1A), an active ingredient of the plant cannabis 
sativa, and an agonist of the cannabinoid receptors, CB1 and CB2, could potentially be such a dual 
acting anti-glaucoma agent [123-125]. The presence of cannabinoid receptors in the ocular tissues 
have been recently identified [126] lending support to a localized IOP reducing mechanism, rather 
than central nervous system involvement. What makes THC especially attractive is that in addition 
to its IOP lowering activity, THC has also demonstrated independent neuroprotective potential 
[79].  
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In terms of the route of delivery, since glaucoma is a chronic disease, non-invasive topical 
application would be the most preferred means of drug delivery.  The anatomy and physiology of 
the eye, however, presents a formidable barrier to intraocular delivery of drugs, especially to the 
back-of-the eye which is needed for neuroprotectant activity, through the topical route. The 
combination of precorneal and corneal barriers, and other physiological barriers, results in only 
about 5-10% of the topically applied drug reaching the inner ocular tissues [94, 95, 127]. 
Development of THC as an eye drop is especially challenging due to its poor aqueous solubility 
(1-2 µg/mL) and high logP (6.42) [128]. In view of the challenges in topical delivery of THC it is 
not surprising that disparity exists in the literature with respect to the efficacy of THC administered 
through the topical route [129-131]. Some reports showed IOP lowering activity of THC in 
normotensive rabbits [130], ocular hypertensive human subjects [132], rabbit glaucoma model 
[133], normotensive dogs [134] and normotensive cats [135], while several other studies showed 
no IOP lowering activity in normal human subjects [129, 136], glaucoma models [137]. In fact, 
based on the earlier data a study panel constituted by the National Eye Institute of the National 
Institutes of Health had concluded that there was insufficient evidence to conclude that THC could 
be useful in the treatment of glaucoma [138]. 
Review of the literature revealed that in most of these earlier studies evaluating the efficacy 
of THC through the topical route, researchers used mineral oil or surfactant based solutions or 
emulsions as the formulation platform. While these formulations improved solubility of THC they 
would not alter its membrane permeation characteristics. Taking into consideration the 
formulations used and the associated preclinical data, we hypothesized that THC, because of its 
lipophilic characteristics, would rapidly partition into the lipophilic corneal epithelia but would 
remain trapped there – failing to efficiently partition out into the more hydrophilic stromal layers 
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- and not reach the intraocular tissues [139]. Thus, we started evaluating various THC prodrugs to 
enhance ocular tissue permeation characteristics of THC. 
We previously synthesized and studied dicarboxylic acid prodrugs, the hemisuccinate 
(THC-HS) and the hemiglutarate (THC-HG) esters, to improve ocular bioavailability [79]. A 
significant improvement in aqueous solubility was observed due to the ionization of the molecules 
at physiological pH. Transcorneal permeability, however, remained low at physiological pH. Use 
of ion-pairs, which shielded the negative charge of THC-HG at physiological pH, significantly 
improved permeability at pH 7.4. Topical administration of THC-HG in rabbits using these ion-
pair formulations delivered THC to the front of the eye tissues, such as aqueous humor and the 
iris-ciliary bodies. THC levels were below detection levels in the retina and vitreous humor [139].  
In contrast to the dicarboxylic acid prodrugs, the amino acid THC prodrugs has shown 
greater stability, especially the valine ester, but low aqueous solubility at physiological pH [140]. 
Figure 3.1: Chemical structures of A) Δ9-Tetrahydrocannabinol (THC), B) Δ9-
Tetrahydrocannabinol Valine (THC-Val), C) Δ9-Tetrahydrocannabinol Valine Valine (THC-Val-
Val) and D) Δ9-Tetrahydrocannabinol Valine Hemisuccinate (THC-Val-HS). 
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Thus, THC-Val (Fig.3.1B) and THC-Val-Val (Fig.3.1C) were included in this study. Their ocular 
penetration and solubility in the presence of surfactants and cyclodextrins have been evaluated. 
However, due to poor aqueous solubility, Val and Val-Val were not evaluated further. 
Additionally, to overcome the drawbacks observed with the dicarboxylic acid esters and the 
solubility limitations of the amino acid prodrugs, a new amino acid-dicarboxylic acid prodrug, 
THC-Val-HS (Fig.3.1D), was designed.  
The preformulation characteristics and ocular tissue homogenate stability and IOP 
lowering activity of the most promising compound was tested in alpha-chymotrypsin induced 
rabbit glaucoma model. Therapeutic activity was compared to that of the controls - THC, timolol 
maleate and pilocaprine eye drops (the latter two being marketed ophthalmic formulations).  
3.2. MATERIALS AND METHODS 
3.2.1. Materials 
Hydroxypropyl methyl cellulose (HPMC, 4000 cps), 2-Hydroxypropyl-β-cyclodextrin 
(HPβCD), randomly-methylated-beta-cyclodextrin (RMβCD), Tyloxapol and alpha-chymotryspin 
(Type II, lyophilized powder, ≥40 units/mg protein) were purchased from Sigma-Aldrich (St. 
Louis, MO). Super Refined™ Tween 80™ was received as a gift sample from Croda Inc. (Mill 
Hall, PA). Pluronic® F 68 (Poloxomer 188), Pluronic® F 127 (Poloxomer 407) and Cremophor® 
RH 40 were received as a gift sample from BASF (Florham Park, NJ). Tocrisolve™100 was 
purchased from Tocris Biosciences (Minneapolis, MN). Timolol maleate eye drops (0.25 % w/v) 
and Pilocarpine HCl eye drops (2 %w/v) were marketed eye drops. All other chemicals and 
solvents were purchased from Fisher Scientific (St. Louis, MO).  
Buffer reagents used in the cannabinoid receptor binding studies were purchased from 
Sigma-Aldrich (St. Louis, MO). All radioligands and MicroScint™ were purchased from 
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PerkinElmer (Waltham, MA). Non-labeled controls were purchased from Tocris Bioscience 
(Minneapolis, MN). Membrane preparation was made using a Tris-HCl buffer (50 nM Tris-HCl), 
pH 7.4. Dilutions of membrane, radioligand and control/test compounds were made in a Tris-
EDTA buffer (50mM Tris-HCl, 20mM EDTA, 154mM NaCl and 0.2% fatty-acid BSA), pH 7.4.   
In vitro transcorneal permeability studies were carried out using corneas of New Zealand albino 
rabbits (isolated from whole eye globes) delivered overnight on wet ice in Hanks Balanced Salt 
Solution from Pel-Freez Biologicals® (Rogers, AK). The tissues were used on the day of receipt 
[139]. 
3.2.2. Animals 
Male New Zealand albino Rabbits (2-2.5 kg) were procured from Harlan laboratories® 
(Indianapolis, IN). All animal experiments conformed to the tenets of the Association for Research 
in Vision and Ophthalmology statement on the Use of Animals in Ophthalmic and Vision Research 
and followed the University of Mississippi Institutional Animal Care and Use Committee approved 
protocols. 
3.2.3. Synthesis and characterization of Δ9-Tetrahydrocannabinol Prodrugs 
THC-Val, THC-Val-Val and THC-Val-HS were synthesized as per previously established 
protocols [140]. The final product was purified using column chromatography and characterized 
by mass spectroscopy in the positive ionization mode. Identity and purity of the synthesized 
prodrugs was established by spectral means including 1H-NMR, 13C-NMR and 2D-NMR such as 
correlation spectroscopy (COSY), Heteronuclear single-quantum correlation spectroscopy 
(HMQC), Heteronuclear multiple-bond correlation spectroscopy (HMBC), as well as other 
spectroscopic means as reported earlier [140]. 
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3.2.4. Stability of THC-Val-HS in Ocular Tissue Homogenates 
3.2.4.a. Tissue Preparation 
Aqueous humor and vitreous humor was used as such. Retina choroid and iris ciliary bodies 
used in this study were homogenized in ice cold IPBS, on an ice bath, using TISSUEMISER 
(Fisher Scientific, St Louis, USA). The homogenate was then centrifuged at 13000 rpm at 4 °C for 
15 min. Protein content in the supernatant was determined according to the method of Bradford 
[103] and were standardized to 1 mg/mL approximately. 
3.2.4.b. Hydrolysis Procedure 
The tissue homogenates were equilibrated for 30 min at 37 °C to activate the enzymes. To 
1.9 mL of the supernatant, 100 µL of THC-Val-HS (2 mg/mL) in ethanol was added and mixed. 
Hundred microliters of samples were withdrawn at specific time intervals up to 6 h post initiation. 
An equal volume of ice cold acetonitrile was added to the samples, to arrest the reaction, and 
centrifuged at 13,000 rpm for 15 min. The supernatant was collected and analyzed using HPLC-
UV method described under section Analytical Method for In vitro Studies. 
3.2.5. Formulations 
An accurately weighed amount of THC and/or the prodrug was dissolved in light mineral 
oil, NF, to prepare the mineral oil based formulation. Emulsion-1 (THC) formulations were 
prepared according to previously published protocols [141]. Tocrisolve™ emulsion formulations 
were prepared by dispersing known amount of THC or prodrug in the emulsion and sonicating for 
30 sec followed by stirring for 2 min. Micellar solutions were prepared by dissolving the 
drug/prodrug in HPβCD solution in IPBS (pH; 7.4) for 24 h and adding Cremophor® RH 40 in it 
and mixing for 2 min. Weighed amounts of BAK and EDTA were also added and the final volume 
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was made up with IPBS (pH: 7.4). All the formulations used for the IOP efficacy studies are listed 
under table 3.1.  
 
 
3.2.6. Efficacy studies 
Open angle glaucoma was induced in New Zealand white rabbits (weighing about 2-2.5 
kg). Rabbits were anesthetized by intramuscular injection of Xylazine (3.5 mg/ kg), and Ketamine 
(35 mg/kg). Chronic open ocular glaucoma was induced by a single posterior injection of alpha-
chymotrypsin (20 mg/mL, 50 µL) into the vitreal cavity [142, 143]. Care was taken to avoid the 
Ingredients THC THC-Val-HS Timolol maleate 
Pilocarpine 
HCl 
(%w/v) Tocrisolve Emulsion 
Tocrisolve 
Emulsion 
Micellar 
solution 
Aqueous 
solution 
Aqueous 
solution 
Drug/Drug 
canditate 0.37 (THC) 
0.6 (THC 
equivalent) 
0.55 (THC 
equivalent) 0.25 2 
Soyabean oil 14 14 - - - 
Oleic acid 6 6 - - - 
Glycerine 2.25 2.25 - - - 
Poloxamer 188 2 2 - - - 
Lipoid E 80 1 1 - - - 
α-tocopherol 0.02 0.02 - - - 
Cremophor® 
RH 40 - - 0.25 - - 
HBβCD - - 15 - - 
HPMC - - 0.5 - X 
BAK - - 0.02 0.01 - 
EDTA - - 0.1 - X 
NaH2PO4 - - - X X 
Na2HPO4 - - - X X 
Table 3.1: THC, THC-Val-HS, Timolol maleate and pilocarpine HCl formulations used for in 
vivo efficacy studies in alpha chymotrypsin induced rabbit glaucoma model. 
HPβCD: (2-Hydroxypropyl)-β-cyclodextrin, HPMC: Hydroxypropyl methyl cellulose, BAK: 
Benzalkonium chloride, EDTA: Ethylenediamine tetra acetic acid, Na2HPO4: Dibasic sodium 
phosphate and NaH2PO4: Monobasic sodium phosphate. 
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contact of alpha-chymotrypsin with the surface of the eye. Daily ocular examination was 
conducted for a few days. Following the intravitreal injection, one drop each of ciprofloxacin, 
dexamethasone and diclofenac sodium ophthalmic solutions were instilled for about 5 days to 
prevent topical inflammation. When the elevating IOP was stabilized to 30 ± 3 mmHg 
(approximately 14 days post-intravitreal injection of alpha-chymotrypsin) for three successive 
days, the IOP lowering efficacy studies were initiated.   
For IOP lowering studies, about 50 µL of each formulation was instilled into the lower cul 
de sac of the left eye of the rabbits (n = 3), while the right eye served as control. Immediately after 
instillation the eye lid was closed for 10 seconds in order to avoid spillage of the preparation. IOP 
was measured before instillation (baseline IOP) and every 30 min post instillation till the IOP 
returned to 90% of baseline IOP using Tonovet® tonometer (Reichert Inc.). As a result of alpha 
chymotrypsin, corneal surface of the eye was very flaccid compared to the normal eye. So the 
during the IOP measurement in the glaucomatous eye, tonometer applied with slight pressure. 
Each value is an average of five concurrent measurements, in triplicates, at each time point for 
each animal. Same measurement steps were followed during each time point of the study. The IOP 
determined at each point is reported as the percent baseline IOP (± SEM) i.e. (measured 
IOP/baseline IOP) x 100.  
3.2.7. Cannabinoid Receptor Binding Assay 
Cannabinoid receptor binding studies were carried out as per previously reported methods 
[110, 144] with suitable modifications in order to determine the affinity of the designed prodrug 
in comparison with CP-55,940, a full agonist of CB1/CB2 receptors and THC, the parent 
molecule.  
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3.2.7.1. Cell Culture 
HEK293 cells (ATCC, Manassas, VA) were stably transfected via electroporation with 
full-length human recombinant cDNA (OriGene, Rockville, MD) for cannabinoid receptor 
subtypes 1 and 2. These cells were maintained at 37°C and 5% CO2 in a Dulbecco’s Modified 
Eagles’ Medium (DMEM) and F-12 HAM nutrient mixture (50/50), supplemented with 2 mM L-
glutamine, 10% fetal bovine serum, 1% penicillin− streptomycin, and G418 antibiotic solutions. 
3.2.7.2. Membrane Preparation 
Membranes were made by washing the cells with cold IPBS. The cells were lysed and 
scraped in cold Tris-HCl, pH 7.4 and then centrifuged at 5,200 x g for 10 min at 4°C. The 
supernatant was discarded and the pellet was resuspended in the same buffer and homogenized 
via Sonic Dismembrator Model 100 (Fisher Scientific, Pittsburgh, PA) for 30 seconds and then 
centrifuged at 1,000 x g for 10 min at 4°C. The supernatant was saved and the pellet underwent 
the suspension and homogenization process 2 more times with the same conditions. The 
supernatants were combined and centrifuged at 23,300 x g for 40 minutes at 4°C. The pellet was 
re-suspended in cold Tris-HCl buffer, aliquoted into 2mL vials and stored at -80°C. The total 
protein concentration was determined using a Pierce BCA Protein Assay Kit (Thermo Scientific, 
Rockford, IL) using to manufactures instructions. 
3.2.7.3. Method for Cannabinoid Receptor Binding Assay 
For each assay, non-specific binding was determined using 10μM of CP-55,940 as a 
positive control and total binding was ascertained with 0.1% DMSO in Tris-EDTA buffer. Each 
test well contained 50μL of radioligand ([3H]-CP-55,940), 50μL of compounds, control or vehicle 
and 100μL cell membrane. The assays were incubated for 90 minutes at 37°C with gentle agitation. 
The reaction was terminated via rapid filtration with cold Tris-HCl with 0.1% BSA through a 
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UniFilter GF/C 96-well plate pre-soaked with 0.5% PEI. When the filters were dry, 25μL 
MicroScint-20 was applied to each filter and the plates were read on a TopCount NXT HTS 
Microplate Scintillation Counter (PerkinElmer, Waltham, MA) where the counts per minute 
(CPM) were recorded. 
The Kd for the radioligand for each receptor was established through a membrane 
evaluation and saturation binding experiment. For the membrane evaluation experiment 1-10 μg 
of membrane was incubated with 1 nM of [3H]-CP-55,940. For the saturation assay, the optimal 
membrane concentration and 0-10 nM of [3H]-CP-55,940 was incubated with 10 μM of a non-
labeled CP-55,940 or 0.1% DMSO in buffer. Data was analyzed by a non-linear curve fit model 
using GraphPad Prism 5.04 software (GraphPad, La Jolla, CA) and the Kd value was calculated. 
The competitive binding assay was performed using the optimal concentration of membrane with 
a radioligand concentration equal to the Kd, and concentrations of each compound ranging from 
0.00032-100 μM. Each compound was tested in triplicate. The assays were performed as stated 
above. The IC50 and Ki values were calculated by a non-linear curve fit model using GraphPad 
Prism 5.0 software. 
3.2.8. Data Analysis 
Difference in variance between the groups was checked with Levenes test before carrying 
out ANOVA. Statistical significant difference among multiple groups was checked using one way 
ANOVA. Tukey’s Honestly Significant test was carried out to differentiate between the groups. A 
p value less than 0.05 was considered to be statistically significant.  
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3.3. RESULTS 
3.3.1. Preformulation studies  
The predicted physicochemical properties of THC-Val-HS, THC-Val and THC-Val-Val, 
as well as THC and THC-HG have been depicted in Table 3.2. Considering the critical 
physicochemical properties, THC-Val-HS was expected to be relatively more hydrophilic with 
improved LogDpH 7.4 and higher polar surface area, compared to the other prodrugs. 
3.3.2. Stability of THC-Val-HS in Ocular Tissue Homogenates 
Apparent first order degradation rate constants and half-life of THC-Val-HS in aqueous 
humor, vitreous humor iris ciliary bodies and retina-choroid homogenates have been depicted in 
Table 3.3. THC-Val-HS was rapidly converted to THC in the ocular tissues (t1/2: 46.4 ± 3.1 and 
39.2 ± 10.3 min, respectively).  
 
Table 3.2: Comparison of the predicted physicochemical properties of the dicarboxylic acid 
ester and Amino Acid-dicarboxylic acid ester THC Prodrugs, using ACD/I-Lab 2.0. 
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3.3.3. Efficacy studies  
THC lowered IOP in the glaucoma model, but not in the normotensive rabbits, in a dose dependent 
manner (Fig.3.2). The maximum percent drop in the IOP from the baseline IOP (ΔIOPmax) and 
time for peak IOP reduction (Tmax), both varied depending on the THC dose. With a 0.5% w/v THC 
in Tocrisolve™ formulation, IOP was 66.0 % of the baseline (at 30 min) and rapidly started 
Figure 3.2:  IOP-Time profile for THC in normotensive and α-chymotrypsin induced rabbit 
glaucoma model. Data represents Mean ± SEM. Numbers in brackets represent concentration 
and dose of THC. 
 
Table 3.3: Apparent first order rate constants (k*) and half-lives (t1/2) of THC-Val-HS in 
ocular tissue homogenates. Results are depicted as mean ± SD. 
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returning back to baseline IOP, reaching 89.2 % (at 60 min). The short duration of action observed 
with THC could be due to poor penetration and rapid elimination of THC from the eye. With a 
0.7% THC concentration, a slightly prolonged duration in IOP lowering activity was observed. 
THC (0.8 %w/v), demonstrated further improvement in IOP reduction. The percent baseline IOP 
was 64.8% at 30 min and 66.6% at 60 min. IOP started reverting back to baseline after 60 min, 
reaching 83.7% and 91.0% at 90 min and 120 min, respectively. Tocrisolve™ did not show any 
effect on IOP.  
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Figure 3.3: IOP-Time profile for THC-Val-HS in comparison with THC in rabbit glaucoma 
model. Data represents Mean ± SEM. Numbers in brackets represent concentration and dose of 
THC. 
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With THC-Val-HS emulsion and micellar solution formulations, an improved IOP 
lowering activity was observed (Fig.3.3). At a THC equivalent dose of 0.6 % w/v (THC-Val-HS: 
0.99 %w/v) improved IOP lowering activity, compared to THC, was seen. Though the onset of 
action was delayed, due to slower bioconversion of the prodrug into THC, the duration of action 
was prolonged. The maximum percent change in IOP from the baseline was observed to be at 90 
min and was maintained till the 120 min time point and reverted back to the baseline IOP by the 
end of 240 min. The overall IOP lowering profile was more profound compared to THC, even at 
a lower THC dose. THC-Val-HS formulated in the cyclodextrin + surfactant solution, also showed 
improved IOP lowering activity (THC equivalent dose: 0.55 % w/v). Although the duration of 
activity was slightly shorter compared to the emulsion formulation the overall profile remained the 
same.  
Timolol maleate eye drops showed a prolonged IOP lowering activity lasting for about 6h, 
with a maximum percent IOP change from baseline of 59% (120 min). IOP returned to baseline 
more slowly showing a longer duration of action. THC-Val-HS was slightly better in IOP lowering 
compared to Timolol, though the former showed a shorter duration of action. When compared to 
another marketed anti-glaucoma product, Pilocarpine eye drops, THC-Val-HS showed much 
improved IOP lowering activity (Fig.3.4).  
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3.3.4. Receptor binding studies 
The receptor binding studies showed that the IC50 and Ki for THC-Val-HS was much higher 
than CP-55,940 and THC for both CB1 and CB2 receptors (Fig.3.5). The Ki of CB1 receptors for 
THC-Val-HS (0.960 ± 0.174 µM) compared to that of CP-55,940 (0.003 ± 0.0 µM) and THC 
(0.044 ± 0.005) was found to be 320 and 21.8 folds higher respectively, while Ki for CB2 receptors 
for THC-Val-HS (1.2154 ± 0.0.082 µM) compared to that of CP-55,940 (0.002 µM) and THC 
(0.032 ± 0.001) was about 607.5 and 38 folds higher respectively. The IC50 values for CB1 
receptors for THC-Val-HS (1.593 ± 0.289 µM) compared to that of CP-55,940 (0.005 ± 0.001 µM) 
and THC (0.077 ± 0.008) were found to be 318.6 and 20.6 folds higher respectively, while Ki for 
CB2 receptors for THC-Val-HS (2.430 ± 0.164 µM) compared to that of CP-55,940 (0.004 ± 0.0 
Figure 3.4: IOP-Time profile for THC-Val-HS in comparison with Timolol maleate and 
Pilocarpine eye drops (marketed) in rabbit glaucoma model. Data represents Mean ± SEM. 
Numbers in brackets represent concentration and dose.  
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µM) and THC (0.047 ± 0.002) were about 607.5 and 51.7 folds higher respectively. The results 
suggested that the prodrug (THC-Val-HS) has much lower affinity for the cannabinoid receptors 
and the pharmacologically inactive as is.   
 
3.4. DISCUSSION 
We previously reported that 1 hour post topical instillation of THC eye drops, formulated 
in light mineral oil, nanoemulsion or micellar solutions, THC levels in the deeper ocular tissues 
such as the aqueous humor, iris-ciliary bodies, vitreous humor and retina choroid of anesthetized 
rabbits, could not be detected by the analytical method used [79].  A hydrophilic THC ester 
prodrug, THC-HG, formulated as an ion-pair, significantly increased ocular tissue concentrations 
in anesthetized rabbits. THC-HG, however, was not very stable in the formulations tested [141]. 
Initial studies with several amino acid ester prodrugs suggested that the valine ester prodrug was 
significantly more stable. This is consistent with previous literature reports [145, 146]. It had also 
Figure 3.5: Cannabinoid receptor (CB1 and CB2) binding studies of THC-Val-HS, THC 
and CP-55,940. 
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been suggested that addition of an amide linkage to the ester link enhances the stability of the ester 
bond [147]. The combination prodrug THC-Val-HS was thus conceived with the expectation that 
the valine ester would be the most stable and the stability of the ester bond would be enhanced by 
the amide linkage with the hemisuccinate. The hemisuccinate moiety was selected based on the 
fact that it would have the minimum chain length while providing enhanced solubility by virtue of 
ionization at physiological pH. Thus, the overall objective of this study was to evaluate THC-Val-
HS, as well as THC-Val and THC-Val-Val, in terms of its in vivo IOP lowering activity. 
The alpha-chymotrypsin induced rabbit glaucoma model was used to evaluate the in vivo 
IOP lowering activity of THC-Val-HS [142, 143, 148-151]. This model has been widely used to 
study effect of drug and drug candidates on IOP. In an attempt to increase THC loading, compared  
to that achieved with the formulations used for the bioavailability studies (Table 3.1), 
Tocrisolve™, a commercially available optimized emulsion, was used which allowed a 0.8 %w/v 
THC loading. With the THC- Tocrisolve™ emulsion formulation, a dose dependent decrease in 
IOP was observed. The IOP lowering effect duration was, however, short and IOP returned to the 
baseline value within 2h. This is consistent with the ocular distribution data obtained with the 
lower THC doses, showing poor penetration into the intraocular tissues and/or rapid clearance. 
The results however are different from that reported in an earlier study evaluating the effect of Δ8-
THC on IOP [133]. The authors reported that, 50 µL of a submicron emulsion formulation of 0.4 
%w/v ∆8-THC produced a drop of 10.83 ± 2.04 mm of Hg reduction in IOP in an alpha-
chymotrypsin induced rabbit model of ocular hypertension. Moreover, the drop in IOP lasted upto 
8 h in the animal model.  
THC did not show any effect on IOP in normotensive rabbits, suggesting an unique mode 
of action and requires further investigation [152]. Muchtar et al also reported that the drop in IOP 
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in normotensive rabbits with the submicron emulsion formulation was not significant to that 
observed in hypertensive model [133]. Crandall et al, reported that even systemic administration 
of THC (5 mg/kg body weight) did not show any drop in normotensive control eye compared to 
hypertensive eye (approximately 6 mm of Hg drop) [123].  
For THC-Val-HS also the formulations employed in the ocular disposition could dissolve 
only upto 0.25 %w/v THC, which was significantly lower than the THC dose in TocrisolveTM.  
Thus, a new formulation was prepared combining HPβCD (15 %w/v) and Cremophor® RH 40 
(0.25 %w/v) as the solubilizers, which increased the drug loading to 0.55 %w/v THC equivalent 
(THC-Val-HS: 0.9 %w/v). Tocrisolve™ emulsion could load 0.6 % w/v THC equivalent (THC-
Val-HS: 0.99 %w/v).  Both formulations were used to evaluate the effect of THC-Val-HS on IOP.  
THC-Val-HS, administered topically to the alpha-chymotrypsin induced high IOP rabbits, 
displayed a gradual onset of IOP lowering effect and a longer time to achieve maximum effect, in 
comparison to THC. THC-Val-HS exhibited a much longer duration of activity, up to 4h, even at 
a lower THC equivalent dose. The significantly increased duration observed with THC-Val-HS 
could be due to increased penetration of the prodrug into the inner ocular tissues (as seen in the 
ocular distribution studies) and, thus, availability of higher amounts of THC at the target tissues. 
The more gradual achievement of peak IOP reduction could be because of the need for 
regeneration of THC, from the prodrug, in the ocular tissues (Table 3.3). Though both 
Tocrisolve™ emulsion and micellar solution-2 were similar in IOP reduction profile, the former 
was slightly more efficacious than the latter.  
When compared to Pilocarpine HCl and Timolol maleate marketed eye drops, the IOP 
lowering action of THC-Val-HS was equivalent to that of Pilocarpine with equal intensity (if not 
more) and duration of action. Timolol maleate eye drops exhibited a prolonged IOP lowering 
63 
 
activity compared to THC-Val-HS emulsions; however, the latter was more intense in terms of 
maximum IOP reduction. The IOP lowering profiles observed for pilocarpine and timolol was 
similar to that reported in earlier studies [153, 154]. 
The receptor binding studies demonstrated that the THC Val-HS did not have significant 
affinity for both CB1 and CB2 receptors. This indicates that the cannabinoid receptor mediated 
action is solely dependent THC and that THC-Val-HS does not act as a THC analog. This is 
consistent with the gradual IOP lowering profile and the delayed maximum drop in IOP seen with 
THC-Val-HS as a result of dependence on THC regeneration.  
Thus, the present study demonstrates that a rational combination of prodrug design and 
formulation strategy can effectively deliver THC to the anterior chamber of the eye. An increased 
IOP reduction with the prodrug at lower equivalent doses of THC, supports improved ocular 
penetration of the prodrug. Importantly, with most of the conventionally developed anti-glaucoma 
drugs having no reported neuroprotective action, THC, an established neuroprotectant, has the 
potential to become an effective glaucoma medication. Further studies are currently aimed at 
developing and optimizing various formulations with improved THC delivery to the back-of-the 
eye. 
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CHAPTER 4 
 
4.1. INTRODUCTION: 
Cyclodextrins (CD’s) are a group of cyclic oligosaccharides with a hydrophobic inner core 
and a hydrophilic outer surface. Based on the number of glucopyranose units in the structure, they 
are classified into alpha (α), beta (β) and gamma (γ) CD’s (6, 7 and 8 units respectively). Over the 
last few decades, CD’s have emerged as an important pharmaceutical excipient for solubility 
enhancement of lipophilic drugs and permeability improvement across biological membranes 
[155]. CD’s act as penetration enhancers by increasing the availability of drug molecules at the 
surface of the biological membrane barrier. Because of their aqueous solubility improving 
characteristics, suitable cavity size and drug complexation efficiency [155], beta-cyclodextrins 
(βCD’s; Fig.4.1A)  such as hydroxypropyl beta cyclodextrin (HPβCD; Fig.4.1B) and randomly 
methylated beta cyclodextrin (RMβCD; Fig.4.1C) are widely used in the field of formulation and 
drug delivery.  
It is only recently that the mechanism of permeability enhancement across biological 
membranes, such as skin, buccal mucosa and cornea, have been discussed. CD’s interact with 
cholesterol present in the phospholipid monolayers of the cell membranes, thus exchanging them 
with the drugs/drug candidates held in the hydrophobic CD core (Fig.4.5). In addition to their 
utility as transcorneal permeability enhancers, by virtue of their ability to extract lipophilic 
components like cholesterol and phospholipids from the corneal membrane [156], CD’s are often 
added to the receiver solutions to maintain sink conditions during in vitro transcorneal permeability
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studies of lipophilic molecules [157]. Unknowingly damaging the cornea (epithelium, stroma 
lamellae or endothelium), 
however, may lead to altered 
permeability of the drug/drug 
candidates as a result of the 
receiver solution characteristics 
rather than formulation or 
drug/prodrug candidate 
properties. This can lead to 
misinterpretation of the results 
and overestimation of the 
permeability enhancement of the 
formulation/drug candidate if 
adequate controls were not included in the experiment design. Thus, an understanding of the effect 
of CDs on the corneal permeability characteristics, when added as a solubilizer in the receiver 
solution, is very important and has not been analyzed as yet. The aim of the present study is to 
evaluate the effect of CD concentration, duration and type on the morphological characteristics 
and barrier properties, using propranolol hydrochloride (PHCl; Fig.4.1D) as a paracellular 
diffusion marker, of isolated rabbit cornea in vitro.  
4.2.  Methods: 
4.2.1. Phase solubility studies: 
Complexation of PHCl with HPβCD and RMβCD was evaluated using phase-solubility 
studies according to the method of Higuchi and Connors [158]. Excess amount of PHCl was added 
Figure 4.1: Chemical structure of A) General structure of 
beta cyclodextrin (β-CD), B) Hydroxypropyl-βeta-
cyclodextrin (HPβCD), C) Randomly methylated-βeta-
cyclodextrin (RMβCD) and D) Propranolol (PHCl). 
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to 1 mL IPBS, containing increasing concentrations of CDs. The concentrations ranged from 2.5 - 
10 %w/v. The resulting suspensions were shaken at 25°C for 24 h in a reciprocating water bath. 
Following equilibration, the suspensions were centrifuged at 13,000 rpm for 20 min at 25°C and 
the supernatant thus obtained was analyzed using an HPLC-UV method [159].  
Phase-solubility profile was obtained by plotting the solubility of PHCl against the 
concentration of CD’s used. The binding constants (K1:1) and complexation efficiencies (CE) for 
the PHCl-CD complex were calculated from the linear region of the solubility curves using 
Equation 1 & 2: 
𝐾𝐾1:1 = 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑜𝑜(1−𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆)      Eq (1) 
𝐶𝐶𝐶𝐶 = 𝐾𝐾1:1 𝑥𝑥 𝑆𝑆𝑆𝑆 = 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆(1−𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆)     Eq (2) 
Where K1:1 is the binding constant, So is the saturation concentration of PHCl in water, and slope 
denotes the slope of the straight line. 
4.2.2. In vitro transcorneal permeability:  
A series of in vitro transcorneal permeability studies were carried out using 9 mm side-by-
side diffusion apparatus (PermeGear Inc., Hellertown, PA).  Freshly excised rabbit whole eye 
globes received from Pel-Freez Biologicals® were used for these studies. Briefly, corneas were 
excised by making a brief incision, about 2 mm from the corneal-scleral junction and cutting 
radially along the sclera. The excised corneas were immediately mounted between the diffusion 
cells. The half-cell facing the epithelial layer was termed as the donor compartment and the other 
half towards the endothelium was termed as receiver chamber. The nomenclature is based on the 
addition of PHCl to the epithelial side half-cell. A circulating water bath was used to maintain the 
temperature at 34 °C during the transport studies.  
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In vitro transcorneal permeability studies were carried out with 2.5 and 5 %w/v HPβCD 
and RMβCD in IPBS (pH 7.4) for 1 or 3h at 34 oC. PHCl (1 mg/mL) was used as the paracellular 
marker (PHCl; pKa = 9.4). PHCl solution was always added on the donor side. Permeation studies 
were performed with IPBS as control; with CD’s on donor side only, CD’s on receiver side only 
and CD’s on both donor and receiver sides as represented in Table 4.1. Aliquots, 600 µL, were 
withdrawn at predetermined time points for 1 or 3 h and replaced with an equal volume of the 
receiver solution. Samples were analyzed by HPLC-UV system [159]. 
4.2.3. Corneal Histology:  
Histological evaluation was carried out at Excalibur Pathology Inc. (Oklahoma City, OK). 
At the end of each study, corneas were fixed in 2 %w/v paraformaldehyde and 2 %v/v 
gluteraldehyde in IPBS. Corneas embedded in paraffin were sliced into 5 µm cross sections using 
a microtome (American Optical® 820 Rotary Microtome). These sections were mounted on a slide 
and dried overnight in an oven. The slide was washed with xylene to remove paraffin and washed 
with alcohol and water to hydrate the tissue. This was then stained with nuclear dye Gill III 
hematoxylin (StatLab medical) for 10 min and rinsed, and then counterstained with eosin. These 
slides were then washed in reverse manner (running water, alcohol, and xylene), cover slipped and 
examined under microscope (Chromavision ACIS II). 
4.3. Results: 
4.3.1. Phase solubility studies: 
 Binding constants of PHCl with HPβCD and RMβCD were very low (278.1 and 326.4 µM-
1 respectively). Complexation efficiency of PHCl with HPβCD and RMβCD were 0.94 and 1.1 
respectively. RMβCD was observed to have slightly higher CE with PHCl than HPβCD. Low 
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binding constant values demonstrate that only a low fraction of PHCl was bound to either of the 
CDs and that there was more free concentrations of CDs and PHCl in the solution. 
4.3.2. CDs on receiver side: 
With 5 %w/v HPβCD and RMβCD on the receiver side permeability coefficient of PHCl 
at the end of 1 h was found to be 40.8 ± 5.7 x 10-6 cm/sec and 52.1 ± 8.4 x 10-6 cm/sec respectively 
(1.5-fold and 1.9-fold higher than the control) (Table 4.1 and Fig.4.2). Similar results were 
encountered with the use of 2.5% w/v HPβCD and RMβCD on the receiver side at the end of 1h 
(32.2 ± 4.9 x 10-6 cm/sec and 41.3 ± 6.6 x 10-6 cm/sec respectively).  
Histological studies at the end of 1 h, revealed damage to both endothelium and epithelium 
in case of 5 %w/v HPβCD on the receiver side. Stroma lamellae were found to be disrupted at 
several points on the cornea. When 5% w/v RMβCD was used on the receiver side less damage 
was caused to the epithelium, and little or no damage to the endothelium was observed. HPβCD at 
2.5% w/v caused significant rupture of the corneal epithelium, but the endothelium was found to 
Table 4.1: In vitro transcorneal permeability coefficients of PHCl at different concentrations 
of CD’s. I) IPBS without CD’s (control; 1), II) CD’s in donor solution (3 & 6), III) CD’s in 
receiver solution (2 & 5) and IV) CD’s in both donor and receiver solutions (4 & 7). 
Experiments were carried out for 1 h or 3 h. * - Experiments were carried out for 1 h and 3 h. 
Permeability coefficients were calculated only for 1 h experiment. 
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be intact. At the same concentration, RMβCD showed little damage to the epithelium and none to 
the endothelium. These studies revealed that more damage was caused when HPβCD is used in 
the receiver solution in comparison to RMβCD (both 5% w/v and 2.5% w/v) (Fig.4.3 & 4.4).  
 
4.3.3. CDs on donor side: 
The permeability coefficients of PHCl at the end of 1 h with 5 %w/v HPβCD and RMβCD 
were found to be 8.1 ± 1.2 x 10-6 cm/sec and 14.5 ± 5.2 x 10-6 cm/sec. Permeability coefficient of 
PHCl in IPBS (control) was found to be 27.02 ± 1.2 x 10-6 cm/sec. Permeability coefficients of 
PHCl were also observed to be lower than the control in case of 2.5% w/v HPβCD and RMβCD 
(Table 4.1 and Fig.4.2).  
Figure 4.2: In vitro transcorneal permeability coefficients of PHCl at different 
concentrations of CD’s. I) IPBS without CD’s (control; 1), II) CD’s in donor solution (3 & 
6), III) CD’s in receiver solution (2 & 5) and IV) CD’s in both donor and receiver solutions 
(4 & 7). 
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Histological studies revealed rupture of the corneal epithelium with the use of 5% w/v and 
2.5% w/v HPβCD in the donor solution. With 5% w/v and 2.5% w/v RMβCD on the donor side 
little or no damage was caused to the corneal epithelium. In case of control group, corneal 
morphology was found to be intact. In all the studies HPβCD and RMβCD in the donor chamber, 
at the concentrations used, did not cause any damage to the endothelium (Fig.4.3 & 4.4).  
Figure 4.3: Hematoxylin-eosin stained corneal cross-sections 1 h post exposure to 1) IPBS: 
control A, 1A) 5% w/v HPβCD in receiver solution, 2A) 5% w/v HPβCD in donor solution, 
3A) 5% w/v HPβCD in receiver and donor solutions, 4A) 5% w/v RMβCD in receiver solution, 
5A) 5% w/v RMβCD in donor solution and 6A) 5% w/v RMβCD in receiver and donor 
solutions. 
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4.3.4. CDs in both donor and receiver chamber: 
Surprisingly, use of 5 %w/v and 2.5 %w/v RMβCD in both donor and receiver chambers 
simultaneously, did not show significant difference compared to the control. Permeability 
coefficients of PHCl in control, 5 %w/v HPβCD and 5 %w/v RMβCD solutions on the donor and 
the receiver sides were observed to be 27.0 ± 1.3 x 10-6 cm/sec, 17.6 ± 1.1 x 10-6 cm/sec and 24.5 
± 3.4 x 10-6 cm/sec respectively. Permeability coefficients of PHCl in control, 2.5 %w/v HPβCD 
and 2.5 %w/v RMβCD solutions on the donor and the receiver sides were observed to be 21.3 ± 
Figure 4.4: Hematoxylin-eosin stained corneal cross-sections 1 h post exposure to 1) IPBS: 
Control B, 1B) 2.5% w/v HPβCD in receiver solution, 2B) 2.5% w/v HPβCD in donor solution, 
3B) 2.5% w/v HPβCD in receiver and donor solutions, 4B) 2.5% w/v RMβCD in receiver 
solution, 5B) 2.5% w/v RMβCD in donor solution and 6B) 2.5% w/v RMβCD in receiver and 
donor solutions. 
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1.03 x 10-6 cm/sec, 13.8 ± 0.9 x 10-6 cm/sec and 19.2 ± 2.7 x 10-6 cm/sec respectively. On an 
average, a 20% drop in the permeability was observed as a function of 50% drop in CD 
concentrations.  
No damage was observed to the corneal epithelia with 5% w/v and 2.5% w/v RMβCD. At 
the end of 1h, when 5% w/v and 2.5% w/v HPβCD solution was used in both donor and receiver 
chambers, the corneal epithelia were found to be damaged. In all cases endothelia was found to be 
intact without any significant damage compared to the control (Fig.4.3 & 4.4). When corneas were 
exposed to 2.5% w/v HPβCD on both sides for 3h, complete erosion of the epithelium was 
observed, exposing the stroma. But no significant damage to the endothelium was noted (Fig.4.5).  
 
4.4. Discussion: 
Figure 4.5: Hematoxylin-eosin stained corneal cross-sections 3 h post exposure to 1) IPBS: 
control, 1B) 2.5% w/v HPβCD in receiver and donor solutions and 2B) 2.5% w/v RMβCD in 
receiver and donor solutions. 
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CDs have become important pharmaceutical excipients due to their ability to improve 
solubility of lipophilic molecules and to enhance permeability across biological membranes. It is 
considered that CD’s increase permeability across biological membranes through their surface 
activity, membrane partitioning and cholesterol extraction characteristics [160, 161].  
In the present study, we used rabbit corneas because of their similarities to human corneal 
ultra-structure [162] and common use in in vitro studies evaluating corneal drug penetration. We 
selected HPβCD and RMβCD because of their widespread use in the ocular formulations and 
permeability studies. Permeability coefficients of PHCl were in the order of CD’s on receiver side 
> control > CD’s on both sides > CD’s on donor side. Corneal histology revealed the damage to 
Figure 4.6: Extraction of cholesterol and the exchange of active moiety by cyclodextrins from 
the phospholipid cell membrane. 
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the membranes in the order of CD’s on receiver side > CD’s on donor side > CD’s on both sides 
> control. CD’s after forming inclusion complexes are known to improve permeability of 
compounds across the biological membranes. Thus, we observed higher permeability coefficients 
with the RMβCD-PHCl complex which could be because of the higher CE of PHCl with RMβCD 
compared to HPβCD.  
RMβCD produced less corneal damage than HPβCD. This is in agreement with previous 
literature reports. Savolainen et al. studied toxicity/irritation caused by CD’s on human corneal 
epithelial cell lines and observed that the cytotoxic effect were in the order of   αCD > Dimethyl-
βCD >SBEβCD = HPβCD > γCD [163]. In another study, Lopez et al. performed a computational 
simulation of CD’s interacting with cholesterol (Fig.4.6) [164]. It was reported that within 10 ns 
of the initial interaction, CD’s orient in a perpendicular direction to the surface of the phospholipid 
monolayer and the hydroxyl groups of membrane cholesterol penetrate into the inner core of the 
CD. On an average, rate of extraction of 1 cholesterol molecule per CD was found to be 0.5 µs. 
Based on the stoichiometric ratios, it was observed that one HPβCD is required to extract one 
molecule of cholesterol or membrane lipid forming a 1:1 soluble complex [165]. In some cases, 
two molecules of CD interact with one another in a head-head, head-tail or tail-tail fashion to form 
a dimer [166]. Both head-tail and tail-tail interactions are less stable than head-head interactions 
due to their spontaneous dissociation in water. Tsamaloukas et al. reported that extraction of one 
molecule of cholesterol/membrane lipid requires two molecules of RMβCD stoichiometrically 
(cholesterol: RMβCD::1:2), since the formation of 1:1 complex is not a spontaneous process [167]. 
These reports suggest that at a given concentration, number of cholesterol molecules extracted per 
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RMβCD are less compared to HPβCD. This could probably explain why RMβCD caused less 
damage to the corneal membranes.  
Besides the type of CDs used, the duration of contact and concentration used are other 
important parameters. Duckner et al. studied the effect of HPβCD concentration on porcine corneal 
endothelium [168]. It was observed that use of 10 %w/v HPβCD caused high grade of endothelial 
damage followed by minimal damage with 1 %w/v HPβCD and none with 0.1 %w/v HPβCD 
within 3 h of the study. Similar observations were recorded in our studies also. In the current report, 
use of 5 %w/v HPβCD caused severe damage to the corneal epithelium and endothelium layers 
within 3 h of exposure. Disruptions in the stromal lamellae were also observed when CD’s were 
employed in the receiver media. Damage to the corneal layers was observed to be minimum with 
the use of 2.5 %w/v CD’s. In our study, we observed that 2.5 %w/v RMβCD causes minimal 
damage compared to HPβCD, but only after 3h of exposure. 
In the current study, permeability coefficients of PHCl were found to be higher when CD’s 
were taken on the receiver side rather than on donor side. This was attributed to the fact that corneal 
endothelium is more permeable when compared to the epithelium [169]. Due to the concentration 
gradient, CD’s incorporated in the receiver side, probably cross the endothelium and stroma and 
interacts with basal cells and tight junctions of the corneal epithelium; thus causing more damage 
to the epithelia and endothelia. In contrast, CD’s on the donor side are unable to pass through the 
non-keratinized squamous cells of the epithelia; thus causing less damage to the cornea. When 
CD’s were employed on both donor and receiver side, due to the absence of net concentration 
gradient, little or no change was observed in the corneal integrity. But prolonged exposure (3 h) to 
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CD solutions leads to the loss of the ZO-1 initiating significant damage and complete erosion of 
corneal epithelium. As a result, we observed severe damage of the corneal epithelia after 3 h 
exposure of the cornea to both HPβCD and RMβCD. 
Several studies in the literature, including some from our own laboratory, have used CDs 
in the receiver solution during in vitro transcorneal permeability evaluation [94, 156, 170-173]. In 
view of the findings from this study, it is apparent that use of CDs as solubilizers in the receiver 
solution could significantly impact transcorneal flux. Thus, it is very important to understand and 
use proper controls and experimental design during in vitro transcorneal permeability studies using 
CDs.  
4.5.  Conclusion: 
The effect of CD’s on corneal membrane in vitro was observed to be dependent on factors 
such as type of CD’s employed, type of inclusion complex formed, CD concentration and the 
duration of exposure to the biological membrane. Thus, the use of CD’s in in vitro transcorneal 
permeation experiments as solubilizers in the receiving medium, especially when used only on one 
side of the tissue, needs to be carefully considered to avoid confounding effects in the permeability 
data obtained due to damage to the corneal ultra-structure.  
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CHAPTER 5 
 
DICLOFENAC SODIUM AND ION EXCHANGE RESIN COMPLEX 
LOADED MELT CAST FILMS FOR SUSTAINED RELEASE OCULAR 
DELIVERY
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CHAPTER 5 
 
5.1. INTRODUCTION: 
Ion exchange resins (IR) are water insoluble cross linked polymers with ionizable groups 
that can be exchanged to form complexes [174]. They are differentiated into anionic and cationic 
exchange resins based on the charge of the exchangeable ionic group [175]. The strong cation 
exchangers such as AmberliteTM IRP69 contain sulfonic acid functional groups, while the weak 
cation exchange resins such as AmberliteTM IRP64 and IRP88 contain carboxylic acid functional 
groups. Similarly anion exchange resins are also divided into strong exchange resins with 
quaternary ammonium groups attached to the matrix such as DuoliteTM AP 143/1083 (Fig.5.1) and 
Amberlite® IRA-410. Weak anion exchangers such as Dowex® WGR-2, Amberlite® IRA-67 have 
tertiary amine substitutes.  
In the past, IR’s were used primarily in the field of agriculture and for the purification of 
water [176]. Application of IR’s as excipients in the field of medicine started when synthetic ion-
exchange resins were used as taste masking and as stabilizing agents in oral dosage forms [177-
180]. Drug-IR complexes show a modified release profiles when compared to the release with the 
drug [181]. Saunders and Srivatsava studied the complexation efficiencies and release kinetics of 
alkaloids from IR’s and suggested that IR’s can be used as suitable carriers for the development of 
sustained-release formulations [182]. Sriwongjanya and Bodmeier have studied the complexation 
of propranolol hydrochloride and diclofenac sodium (DFS; Fig.5.1) by Amberlite® IRP 69 and 
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Duolite® ATP-143, respectively. These drug IR complexes were loaded in hydroxyl propyl methyl 
cellulose (HPMC) matrix tablets to slow their release and achieve a sustained release profile [175].  
The use of IR’s in the field of ophthalmic formulations, however, has been given little 
interest. In the present study, we are using drug-IR complexes loaded into polymeric melt cast 
films to deliver DFS into the eye for prolonged periods of time.  DFS belongs to the class of drugs 
known as nonsteroidal anti-inflammatory drugs (NSAIDs) and are used to treat swelling (anterior 
inflammation) of the eye after cataract surgery [183]. DFS is also used after corneal refractive 
surgery [184] to temporarily relieve pain and photophobia (sensitivity to light). One drop of the 
current DFS ophthalmic solution formulation is applied to the affected eye, 4 times daily beginning 
24 hours after cataract surgery and continued throughout the first 2 weeks of the postoperative 
period [185]. 
Drug delivery to the eye has always been a challenging task due to various ocular 
physiological and dynamic barriers [99, 186]. Topical ophthalmic solutions have been the most 
accepted and conventional drug delivery system for treating ocular diseases [186]. However, they 
present major challenges when it comes to treating chronic issues such as chronic inflammation, 
dry eye, uveitis, age related macular degeneration, glaucoma and diabetic retinopathy [78, 187]. 
These diseases require long term therapy and frequent administration of eye drops. Conventional 
drops only deliver 5-10% of the applied dose into the anterior segment of the eye because of 
precorneal drainage and other ocular barriers [95, 99]. As a result, the frequency of administration 
of the eye drops is usually 4-6 times based on the severity of the pathological condition of the 
anterior segment of the eye. For posterior segment diseases, although intravitreal injections are 
very successful, they are associated with complications such as pain, infection, endopthalmitis and 
retinal detachment [187].  
81 
 
Thus, there is an unmet need for novel and efficient delivery strategies to prolong the 
duration of action of the drug or drug candidates to the eye. Some of these delivery systems include 
surface functionalized nanoparticles [188, 189], liposomes [190, 191] and matrix films [192-194].  
Of all these formulation strategies matrix films are easy to prepare and are also free of any solvents 
or other additives that might cause unwanted reactions at the site of application.  
Thus, the objective of the present study is to develop a sustained release DFS-IR complex 
(Fig.5.1) loaded polymeric matrix film for once or twice a day application based on the severity 
of the inflammation. Matrix films loaded with free DFS (uncomplexed) or DFS-IR complex or a 
combination of free and complexed DFS (DFS-IR) in various ratios were examined with respect 
to their release profiles. 
5.2. Methods: 
5.2.1. Chemicals: 
PEO [PolyOx® WSR N-10 (PEO N-10), MW: 100,000 Daltons; PubChem CID: 5327147] 
and DuoliteTM AP 143/1083 (Cholestyramine Resin USP; PubChem CID: 70695641) was kindly 
donated by Dow Chemical Company (Midland, MI). DFS (PubChem CID: 5018304) was 
purchased from Sigma Aldrich (St. Louis, MO). Pearlitol® 160 C was obtained from Roquette 
Pharma as gift sample. DFS 0.1% w/v ophthalmic solution was purchased from Akorn 
Figure 5.1: Interaction of Diclofenac sodium (DFS) 1 part in solution with 1 part of DuoliteTM 
AP 143/1083 (resin). Chloride ion from the resin is exchanged for negatively charged 
diclofenac in solution to form DFS-IR complex. 
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pharmaceuticals Lake Forest, IL. All other chemicals were purchased from Fisher Scientific (St. 
Louis, MO).  
5.2.2. Animal tissues: 
Whole eye globes of New Zealand albino rabbits were purchased from Pel-Freez 
Biologicals® (Rogers, AK), shipped overnight in Hanks Balanced Salt Solution over wet ice [139] 
and used on the same day of receipt. 
5.2.3. Animals: 
Male New Zealand albino rabbits (2.0 - 2.5 Kg) procured from Harlan Laboratories® 
(Indianapolis, IN; now known as Envigo) were used in all the studies. All animal experiments 
confirmed to the tenets of the Association for Research in Vision and Ophthalmology statement 
on the Use of Animals in Ophthalmic and Vision Research and followed the University of 
Mississippi Institutional Animal Care and Use committee approved protocols (UM Protocol # 14-
022). 
5.2.4 Preparation of DFS-IR complex: 
Prior to the complex formation IR’s were washed thoroughly with deionized water. To 
activate the resin, they are washed with chloride and hydroxide forms and rinsed with water again. 
The drug-resin complexes were formed by batch process [195]. A concentrated aqueous solution 
of DFS (20 mg/mL) was prepared. To this, accurately weighed amount of resin in three different 
ratios (DFS:IR = 1:2, 1:1 and 2:1) was added and agitated for 24h. DFS-IR complexes, thus formed 
were separated by centrifugation, washed with deionized water to remove unbound drug and dried 
in a desiccator overnight. 
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Percentage of drug bound was calculated by analyzing the amount of drug remaining in the 
supernatant liquid using the equation 1: 
Percentage of bound drug = A1 − A2A3 x100 
Where A1= amount of DFS in initial aqueous solution (mg) 
A2= amount of DFS in supernatant solution (mg) 
A3= amount of IR in the solution (mg) 
To confirm the complexation of DFS with IR, Fourier transmission infrared (FTIR) spectra 
for IR, DFS and DFS-IR complex were obtained using a Cary 660 series FTIR (Agilent 
Technologies) and MIRacle™ Single Reflection ATR (PIKE Technologies).  
5.2.5. Preparation of polymeric matrix film and IR suspension: 
Melt-cast technology was employed in the preparation of the polymeric matrix film. A 
previously published protocol was used to prepare the films [192]. All matrix films were prepared 
with 20% w/w drug load. Briefly, DFS and/or DFS-IR complex was mixed with PEO N10 in 
geometric dilutions to obtain a uniform physical mixture. A 13 mm die was placed over a brass 
plate and heated to 70 °C using a hot plate. The physical mixture (200 mg) was added in the center 
of the die and compressed. The mixture was further heated for 2-3 min. After cooling, 4 mm x 2 
mm sections, each weighing approximately 8 mg and with a drug load of 1.6 mg, was cut out from 
the film. 
IR suspension was prepared by first dissolving the free DFS part into water (pH 7.2). Then 
accurately weighed amount of DFS-IR was added to the solution. Mannitol 4.5% w/v (Pearlitol® 
160 C) was added as tonicity agent. To this 0.5% HPMC (4000 cps) was added as suspending 
Eq (1) 
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agent and kept for stirring until all the HPMC got dissolved. To adjust the pH of the formulation 
to 7.3, 0.1 N hydrochloric acid or sodium hydroxide was used.  
5.2.6. Assay and content uniformity: 
To determine the assay and content uniformity of DFS in the film a static assay method 
was used [195].  A 50:50 mixture of isotonic phosphate buffer saline at pH 7.4 and dimethyl 
sulfoxide was used. Each film segment of 8 mg was placed in sufficiently large enough quantity 
of medium (50 mL) to allow for the API to unload from the resin and sonicated for 15 min. This 
cloudy suspension was kept under constant stirring for 2 h, to allow complete release of the 
complexed drug, and centrifuged at 13000 rpm for 15 min. The supernatant was filtered through 
0.2 µ filter and analyzed for free drug using HPLC-UV method. 
5.2.7. In vitro release and corneal permeability studies 
To study the release profile of DFS from the various formulations Side-A-Lyzer dialysis 
cassettes (10000 Dalton MWCO) were used. A 20 mL glass vial was filled with 18 mL of release 
media (IPBS pH 7.34) and a magnetic stirrer was added to maintain equilibrium.  Films (20 %w/w 
loading; Dose: 1.0 mg) loaded with 100% complexed DFS (1:1::DFS:IR) or with 50% un-
complexed (free) DFS and 50% complexed DFS (1+1:1) were placed in each dialysis cassette. 
Hundred microliters of IPBS was added in the dialysis cassette to wet the film. Similarly in three 
more sets (n=3), 1 mL of 0.1%w/v DFS ophthalmic solution (marketed formulation), 1:1::DFS:IR 
suspension and 1+1:1::DFS:IR complex in suspension (Dose: 1 mg) was added, to evaluate the 
effect of the matrix on the release profile. The glass vials were placed over a magnetic plate. The 
temperature was maintained at 34 ± 2 oC using calibrated hot plates. Aliquots, 0.8 mL, were 
collected at specific time intervals and replaced with an equal volume of release media. Studies 
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were carried out for a period of 24 h. Samples were analyzed using a HPLC-UV method. The 
results from the studies were fit into Zero order, first order and Huguchi models. 
In vitro corneal flux and permeability of DFS from the IR loaded film formulation was 
evaluated using a side-by-side diffusion apparatus (PermeGear, Inc., Hellertown, PA) for a period 
of 6 h. The studies were carried out by sandwiching the film (4 mm x 2 mm; 20 %w/w DFS; 
weighing 8 mg approximately; Dose: 1.6 mg) in between a Spectra/Por® membrane (MWCO: 
10,000 Daltons) and isolated rabbit cornea (Pel-Freez Biologicals; Rogers, AK). Corneas were 
excised from whole eye globes, following previously published protocols [103, 139]. The 
membrane-film-cornea sandwich was then placed in between the side-by-side diffusion cells (the 
chamber towards the Spectra/Por® membrane representing the periocular surface and the chamber 
towards the cornea representing the aqueous humor). In another set up wherein the cornea was 
mounted in between the two half-cells (membrane was not used in this case), 3 mL of DFS control 
solution and 1:1::DFS:IR complex suspension was added to the donor chamber. Phosphate buffer 
was used as receiver media (3.2 mL). The side-by-side diffusion cells maintained at 34 °C using a 
circulating water bath. Six hundred microliters of sample was collected at specific intervals of time 
and analyzed using HPLC method.  
5.2.9. In vivo bioavailability studies 
Male New Zealand albino rabbits weighing between 2.0 - 2.5 Kg were used to determine 
in vivo ocular bioavailability of DFS from the topically instilled formulations. Rabbits were kept 
conscious throughout duration of the study. In these studies, 20 %w/w DFS or DFS-IR loaded 
films were placed in the conjunctival sac of the rabbit eye (weight 8 mg; dose: 1.6 mg), while 1.6 
%w/v DFS-IR suspension (volume: 0.1 mL and dose: 1.6 mg) were administered in the eye. 
Hundred microliters of the 0.1% w/v DFS commercially marketed ophthalmic solution was 
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administered twice with half an hour gap between the two applications (at -30 and 0 min; total 
dose: 200 µg). Initially studies were carried out with 0.1% w/v DFS ophthalmic solution, 
3+1:1::DFS:IR film (3 parts DFS in uncomplexed form and 1 part in complexed form) and with 
uncomplexed DFS film for 4 h. Marketed ophthalmic solution (0.1% w/v 0.1% w/v Diclofenac 
sodium solutions from Akorn Pharmaceuticals, Lake Forest, Illinois) was used just to get an 
estimate of ocular bioavailability of DFS with the solution, but not as control formulation. 
Based on the 4h data obtained, and to determine time dependent ocular tissue 
concentrations of DFS, another set of in vivo studies were carried out for 8h exposure using the 
following formulations: 3+1:1::DFS:IR (3 parts DFS free and one part DFS bound to the IER) 
suspension, matrix films containing 3+1:1::DFS:IR, and uncomplexed DFS loaded films. Matrix 
films containing uncomplexed DFS served as the control for the DFS:IR loaded films The 
compositions of all the formulations used for the in vivo studies are reported in table 5.1.  
Table 5.1: Composition of various formulations of Diclofenac sodium (DFS) used for ocular 
disposition studies. 
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At the end of 4h and 8h post topical application (post last application in case of multiple 
applications), the rabbits were euthanized under deep anesthesia with an overdose of pentobarbital 
injected through the marginal ear vein. The eyes were washed with ice cold IPBS and immediately 
enucleated and washed again. Ocular tissues were separated, weighed and preserved at -80 °C until 
further analysis.  
5.2.11. Analytical procedure for in vitro Samples 
Waters HPLC system with 600 E pump controller, 717 plus auto sampler and 2487 UV 
detector was used. Data handling was carried out using an Agilent 3395 integrator. A 40:60 
mixture of water (pH 3.5-4.0) and ACN was used as mobile phase with Phenomenex Luna® 5 
µm C18 100 Å, 250 x 4.6 mm column at a flow rate of 1.5 mL/min and 276 nm. DFS stock solution 
was prepared in mobile phase. 
5.2.12. Bio-analytical method 
5.2.12.1. Standard solution preparation: 
To 100 µL of aqueous humor (AH) or 500 µL of vitreous humor (VH) and to a weighed 
amount of the cornea, sclera, iris ciliary bodies (IC) and retina-choroid (RC), 20 µL of DFS stock 
solution prepared in mobile phase (0.5, 1, 2.5, 5, 7.5, and 10 µg/mL) was added, vortexed and 
allowed to stand for 5 min. To precipitate the proteins, ice cold ACN was added to the AH and VH 
standards in 1:1 ratio and 1 mL to the cornea, sclera, IC and RC standards. Final concentrations of 
the standard solutions were in the range of 10 - 200 ng/mL for AH; 10 - 100 ng/mL for VH; 20 - 
200 ng/mL: cornea & sclera and 10 - 200 ng/mL: IC & RC. Similarly, blank samples were prepared 
for all the tissues by adding 20 µL of mobile phase instead of standard stock solutions. All samples 
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were centrifuged at 13,000 rpm and 4 oC for 30 min and the supernatant was analyzed using HPLC-
UV. All the standard curves generated an R2 value greater than 0.99.  
5.2.12.2. Sample preparation: 
Approximately 0.1 mL of AH and 0.5 mL of VH was collected from each test eye into 
individual centrifugal tubes. All other tissues, RC, IC, cornea & sclera, from each test eye were 
collected and weighed. Tissues were cut into very small pieces and placed into individual vials. 
Protein precipitation was carried out similar to the standard solution preparation procedure and the 
supernatant analyzed using HPLC-UV method. 
A mixture of water (pH 3.5) and ACN in a ratio of 65:35 was used as the mobile phase and 
Phenomenex Luna® 5 µm C18 100 Å, 250 x 4.6 mm column at a flow rate of 1 mL/min and 284 
nm.  
5.2.13. Data analysis 
All experiments were carried out at least in triplicate. DFS release data was fitted to zero 
order, first order and Higuchi models (Equations 2, 3 & 4). 
Ct = C0 + K0t  
LogCt = LogC0 + Kt/2.303 
Ct = KHt1/2 
Where, 
 C0 & Ct = concentration at time 0 min and t min, 
 K0, K & KH = kinetic constants for zero order, first order and Higuchi models. 
Eq (2) 
Eq (3) 
Eq (4) 
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Drug diffusion parameters across cornea such as cumulative amount (Mn) , rate (R) and 
flux (J) were calculated using previously described method [105].  
Cumulative amount of DFS released from the film was calculated using equation 5 
 
 
Where, 
 n = sampling time point (n=1, 2, 3 and 4… corresponding to 15, 30, 45 and 60…min 
respectively), 
Vr = volume of the medium in the receiver chamber (mL),  
VS = volume of the sample withdrawn at the nth time point (mL),  
Cr(n) = concentration of the drug in the receiver chamber medium at nth time point (µg/mL). 
Steady state flux was determined using equation 6 
  
 Where, 
 M = cumulative amount of DFS (µg), 
 t = time (min), 
 A = surface area of cornea (0.636 cm2). 
Rate of elimination of DFS from ocular tissues for the formulations was calculated from 
the slopes of the concentration obtained at the end of 4h and 8h time points.  
Mn= Vr Cr(n) +  Σ 
x=n 
x=1 
Vs(x-1) Cr(x-1) Eq (5) 
Flux (J) = (dM/dt) 
A 
Eq (6) 
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Statistical analysis was carried out using ANOVA to compare between different groups 
and Tukey’s post-hoc HSD was used to compare differences between two groups. A ‘p’ value less 
than 0.05 was considered to denote statistically significant difference. 
5.3. RESULTS: 
5.3.1. Complexation efficiency: 
DFS was complexed at different ratios with Duolite AP 143 (1:1, 1:2 and 2:1) and agitated 
for 24 h. When the amount of IR used was half the amount of DFS used, only a 49.3 ± 3.9% of 
complexation was observed between DFS and the resin. At 1:1 and 1:2 ratio of DFS:IR a 
complexation efficiency of approximately 99% was observed in both cases (Table 5.2). Thus, all 
further studies using complexed DFS employed 1:1 ratio of DFS: IR.  
 
Formulation Free Drug concentration (mg/mL) 
Amount of drug bound to 
resin (mg/mg) 
Percentage 
drug bound 
Drug 16.02 0 0 
1:2::Drug:resin 0.15 15.87 99.04 ± 0.1 
1:1::Drug:resin 0.49 15.53 99.03 ± 0.1 
2:1::Drug:resin 8.11 7.91 49.34 ± 3.9 
Table 5.2: Percentage drug bound to the resin at different ratios of drug:IR. 
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 FTIR spectra shows DFS binds to Duolite™ AP143. Characteristic peak of DFS at 3430.5 
cm-1 (N-H stretching), 1573.5 cm-1 (N-H bending) & 748.12 cm-1 (C-Cl stretching) were observed 
in the FTIR spectra. DuoliteTM AP 143 displays broad peak at about 3400 cm-1 corresponding to 
the quaternary ammonium bending vibration, peaks at 2850 t0 2900 cm-1 were corresponding to 
CH, CH2 and CH3 stretching vibrations and two bands at 1600 and 1500 cm-1 were corresponding 
to the aromatic ring. The N-H bending and C-Cl stretching were observed in DFS-IR complex 
demonstrating no covalent interaction between the drug and IR. (Fig.5.2).  
5.3.2. Assay and content uniformity studies 
DFS content in all the films was observed to be approximately between 94-103 % of the 
theoretical values. DFS was found to be uniformly distributed within the matrix film (RSD<2.3 
%).  
 
Figure 5.2: FTIR spectra of DFS, DuoliteTM AP 143/1083 (IR) and DFS-IR complex. 
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5.3.3. In vitro release and corneal permeability studies 
Release of DFS from 0.1% w/v ophthalmic solution was 80% within 6 h of the study. 
Percent release of DFS from 1:1 (100% DFS in complex form) and 1+1:1 IR-complex (1 part DFS 
free and 1 part bound to the IER) suspensions was 48.8 ± 2.3 and 72.4 ± 2.9, respectively. With 
the 1:1 and 1+1:1 DFS combination loaded in matrix films 52.7 ± 4.9 and 75.5 ± 3.8 percent of 
the DFS, respectively, was released in 24 h (Fig.5.3).  Release kinetics from each formulation is 
presented in table 5.3.  
 
Flux across the cornea was 10.2 ± 0.2 (0.1% w/v DFS ophthalmic solution), 2.0 ± 0.9 (DFS 
matrix film), 0.4 ± 0.05 (DFS:IR::1:1 film) and 0.7 ± 0.04 (DFS:IR::1+1:1 film) µg/min/cm2.  
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Figure 5.3: Percentage release of DFS up to 24 h form various ion exchange resin 
formulations and marketed ophthalmic solution. 
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Under the settings employed, DFS flux across the Spectra/Por® membrane (representing the 
precorneal loss) was 3.0 ± 0.2 and 5.5 ± 0.6 from 1:1 and 1+1:1::DFS:IR film in 6 h respectively. 
Rate and flux of DFS from various formulations is represented in table 5.4.  
5.3.4. In vivo studies 
Initially, ocular tissue concentrations were evaluated in vivo, 4h post topical application of 
the DFS formulations. Ocular tissue concentrations of DFS were analyzed only in the anterior 
segment of the eye (AH and IC) for the initial study. With 0.1% w/v DFS ophthalmic solution, 
181.4 ± 64.8 and 932.4 ± 422.0 ng of DFS/gm of tissue were detected in AH and IC, respectively, 
Table 5.3: Rate constant and Coefficient of correlation of percentage release of DFS from 
different formulations of DFS fitted into Zero order, first order and Higuchi model. 
Table 5.4: Rate and flux of DFS across isolated rabbit cornea from various formulations. 
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at the end of 4 h. Matrix film with uncomplexed/free  DFS was able to deliver 2.68 ± 0.2 µg and 
2.7 ± 0.06 µg of DFS/gm of tissue to AH and IC respectively. As expected, matrix film with IR 
complex delivered lower amounts of DFS to the anterior segment of the eye due to presence of the 
complexed form. Matrix film with DFS:IR complex was able to deliver 0.9  ± 0.2 and 1.02 ± 0.05 
µg of DFS/gm of tissue to AH and IC respectively.  
To evaluate the sustained release effect of the matrix film with DFS and IR complex, the 
study was carried out for 8 h. DFS free and complexed with IR’s such that 3 parts of the total DFS 
dose was in uncomplexed form and 1 part was bound to the IER’s (3+1:1) in solution was used as 
control. All the tissues including RC and VH were analyzed following the 8 h time point.  DFS 
levels were below the limit of detection in VH with all the formulations tested. Matrix film loaded 
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Figure 5.4A: DFS concentrations form various formulations in Aqueous humor (AH) and iris 
ciliary bodies (IC), 4 h post topical application. Conscious animal model. 
95 
 
with free DFS was able to deliver 0.75 ± 0.06 µg/gm of AH, 0.78 ± 0.35 µg/gm of IC, 7.5 ± 3.4 
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Figure 5.4B: DFS concentrations form various formulations in Aqueous humor (AH) and iris 
ciliary bodies (IC), 8 h post topical application. Conscious animal model. 
Table 5.5: Ocular tissue concentration of DFS obtained from various formulations of DFS. 
AH-Aqueous humor, IC-Iris ciliary bodies, RC-Retina-choroid. NA- not analyzed, ND- 
below detection limit. 
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µg/gm of cornea and 14.6 ± 4.8 µg/gm of sclera. DFS-IR film was able to deliver AH: 0.36 ± 0.06 
µg/g of tissue, RC: 89.2 ± 24.2 ng/g of tissue, IC: 662.6 ± 153.5 ng/g of tissue, Cornea: 2.3 ± 1.4 
µg/gm of tissue and Sclera: 7.02 ± 4.03 µg/gm of tissue. At an equivalent dose, DFS-IR complex 
in solution delivered much lower concentrations than the film. Results from in vivo studies are 
presented in table 5.5 and figure 5.4 A and B.  
Rates of elimination for both AH and IC for the DFS film were twice that of DFS-IR film 
(Fig.5.5 A & B). Rate of elimination of DFS in AH and IC from film were 0.2375 and 0.2347 µg/h 
respectively. While for the film loaded with IR complexes AH (0.0623 µg/h) and IC (0.0441 µg/h).  
5.4. Discussion:  
Use of IRs in the field of drug delivery as taste masking and controlled release excipients 
has been reported. Recently, IR’s have also been used in ophthalmic dosage forms to achieve 
sustained release profiles and improved bioavailability. Jain et al developed a suspension 
formulation of betaxalol hydrochloride (Betoptic® S) by binding it to IR’s Betoptic® S retards 
drug release in the tear, increases retention at the ocular surface and enhances drug bioavailability. 
As a result, Betoptic® S 0.25% is found to be bioequivalent to Betoptic Solution 0.5% in terms of 
lowering of intraocular pressure.  
Our aim in this project was to develop a matrix film loaded with IR’s for immediate and 
sustained release profiles, thus providing both loading and maintenance doses. This could be 
achieved by keeping part of drug in the free or uncomplexed state in the matrix film. In the present 
study, an 8 mg matrix film with a 20% w/w drug load (1.6 mg of drug) was prepared. Of this 1.6 
mg, 3 part (1.2 mg) is maintained in uncomplexed for immediate release and the other 0.4 mg (1 
part) is in the complexed state to provide the sustained release profile. The matrix film by itself 
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adds to the sustained release profile. These amounts can be modified accordingly to achieve the 
required drug release profiles. 
Duolite™ AP143 resin is an insoluble, strongly basic, anion exchange resin supplied as a 
dry powder. It is suitable for use in pharmaceutical applications, both as an active ingredient (for 
adsorption of toxic chemicals) and as a carrier for acidic (anionic) drugs [174]. Since DFS is 
negatively charged in the solution, DFS forms a complex with the positively charged Duolite™ 
AP143. In the present study we evaluated the complexation efficiency of DFS with the resin at 
varying weight ratios of DFS and IR as mentioned in table 5.1. No significant differences were 
observed between 1:1 and 1:2 DFS:IR in terms of complexation efficiency. Thus, further studies 
were carried out using the 1:1::DFS:IR complexation ratio. Additional amounts of free DFS was 
added to provide immediate release.  
In vitro release of DFS from IR complexed formulations show an immediate release profile 
followed by the sustained release profile. A 100% release was observed with the 0.1% DFS 
ophthalmic solution in 24 h. With 1+1:1 complex in film, unbound DFS was released in first 2 h. 
Due to constant equilibrium between the IR and the DFS, a sustained release of remaining DFS 
was observed from the complex in the later part of the release profile. The release of DFS from 
1+1:1 complex in suspended state was slower compared to the film. This can be attributed to the 
greater concentration gradient from the film than the solution formulation. In film the 1.6 mg of 
DFS is concentrated in 4 mm x 2 mm surface area, where as in a solution it is distributed over a 
greater surface and reducing the concentration gradient. DFS:IR::1:1 film and suspension showed 
approximately 33% less release compared to the 1+1:1 complex. This is because of the absence of 
the free DFS and the total DFS was in complexed state, the release was more sustained. Similarly, 
1:1 film showed slightly higher release than the suspension. All the results when fitted into into 
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zero order, first order and higuchi kinetics, it was observed that the 0.1% ophthalmic solution was 
following first order release kinetics with coefficient of relation (R2) 0.9895. But all other 
formulations (1:1::DFS:IR solution, 1:1::DFS:IR film, 1+1:1::DFS:IR solution and 1+1:1::DFS:IR 
film) were best fitted for Higuchi model with coefficient of relations (R2) 0.9894, 0.9913, 0.9871 
and 0.9567 respectively (Table 5.3). This demonstrates that the release from the IR complexes is 
more controlled.  
In vitro transcorneal permeability studies were performed over a period of 6 h. With 
DFS:IR::1:1 film (total 1.6 mg in complexed state) flux across the isolated cornea was 
approximately half of the flux obtained from 1+1:1::DFS:IR film (Of the total dose, 0.8 mg was 
free and 0.8 mg was in complexed state). Presence of free 1 part of DFS in the 1+1:1::DFS:IR film 
was aiding in the increased flux of DFS across the cornea. Similarly, flux with DFS film was higher 
than that of 1+1:1::DFS:IR film. With 1+1:1::DFS:IR film, flux was 1/3rd of the flux obtained from 
the unbound DFS film (Table 5.4). This was because the total dose (1.6 mg of DFS) was in 
unbound state. In case of ophthalmic solution, the total DFS is in solution without any rate 
controlling material for the permeation of DFS across the cornea resulting in high flux compared 
to all other formulations. 
Based on in vitro release and permeability results, 1+1:1::DFS:IR formulations are holding 
DFS for longer duration. For 50% release of DFS to release from the 1+1:1::DFS:IR formulations, 
it is talking approximately 12 h. To improve the % drug release from the formulations, in vivo 
studies were carried out with 3 parts of unbound DFS (1.2 mg) and 1 part (0.4 mg) of IR bound 
DFS out of 1.6 mg dose. Conscious rabbit models were used for the study to keep the active 
lymphatic drainage and tear turnover rate unaffected. When 3+1::DFS:IR complexes in solution  
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were administered, slight increase in the eye blinking was observed in the rabbits compared to the 
ophthalmic solution. As per USP guidelines, any ophthalmic solution preparation containing 
particles greater than 10 µm would be recognized as foreign particle by the eye causing discomfort 
[196]. As a result 3+1::DFS:IR complexes in suspension formulation was causing discomfort to 
the rabbit eye. Polymeric matrix film did not cause any excessive tearing, redness or allergies to 
the eye as reported in our previous study [192]. When 3+1::DFS:IR film was applied to the eye, 
there was no excess blinking or tearing in the rabbits. This is because the particles were embedded 
in the film and did not cause any discomfort to the eye.  
DFS ophthalmic solution was administered into the rabbits to estimate the minimal basal 
levels of DFS, but not as a control. As expected, with 0.1% w/v ophthalmic solution, ocular tissue 
concentrations in AH and IC were very less at the end of 4h compared to other formulations (181.3 
± 64.8 and 932.4 ± 422.01 ng/gm of tissue respectively). Matrix film with DFS gave very high 
ocular tissue concentrations in the AH and IC. These levels were much higher compared to the 
3+1:1::DFS:IR matrix film. The matrix film transforms into gel and starts releasing the drug much 
faster than an IR film. As a result, we can see both AH and IC loaded with DFS in first the 4h post 
topical application of DFS film.  
On the other hand, as 3+1:1::DFS:IR matrix film transforms into gel it starts releasing the 
free drug. Simultaneously, the bound DFS is also exchanged for the counter ions in the tear fluid 
and released into the tissues. IR’s have the ability to form in situ complexes [175]. As a results 
some of the free DFS again starts forming complex to maintain the equilibrium. Because of this 
constant change in the equilibrium the ocular tissue levels obtained from the 3+1:1::DFS:IR film 
were less compared to the DFS film. 
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DFS and 3+1:1::DFS:IR films were evaluated for ocular tissue distribution, 8h post topical 
administration. Along with the above two formulations, 3+1:1::DFS:IR in suspension (same dose) 
was also tested for ocular distribution to evaluate the effect of polymeric matrix film. When 
3+1:1::DFS:IR was administered in suspension state, ocular tissue concentrations achieved  were 
similar (in AH) and less (in IC). This is because the suspension formulation is getting drained off 
from ocular surface due to precorneal loss even before getting released and absorbed from IR. At 
the end of 8 h, with DFS film the levels in AH and IC were higher than the 3+1:1::DFS:IR in 
suspension and in film. But it is very important to note that the rate of elimination of DFS from 
ocular tissues at the end of 4 h and 8 h was much higher in AH and IC from DFS (3.7 and 3.3 fold 
respectively) compared to 3+1:1::DFS:IR film rate of elimination of DFS was less (2.5 and 1.5 
fold in AH and IC respectively). Since there is a constant release of DFS from IR, ocular tissues 
were supplied with DFS continuously. As a result, rate of elimination in these tissues was much 
Figure 5.5A: Rate of elimination of DFS concentrations form 
Aqueous humor (AH) at the end of 8 h post topical application. 
Conscious animal model. 
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less compared to the DFS film. The rate of elimination for the film without IR was very high 
compared to IR loaded film (Fig.5.5 A & B).  
With 3+1:1::DFS:IR in suspension state, there was not enough concentration gradient build 
up and most of the DFS was restricted to cornea and sclera. At the end of 8h, posterior segment 
ocular tissues were also evaluated of DFS concentrations. None of the formulations were able to 
deliver detectable levels of DFS in VH. Film with 3+1:1::DFS:IR was able to deliver very minimal 
but detectable levels of DFS to RC (89.2 ± 24.2 ng/gm of tissue).  
According to Blanco et al, half-maximal inhibitory concentration (IC50) values of DFS for 
inhibiting COX-1 and COX-2 enzymes are [197] 0.611 µM (194.4 ng/mL) and 0.63 µM (200.4 
ng/mL). DFS concentrations obtained from both solution formulations in AH were below IC50 
levels. Both films with uncomplexed DFS and with a combination of free and complexed DFS:IRs 
were able to maintain significant levels of DFS in the ocular tissues even at the end of 8 h post 
topical application. Additionally, rate of elimination from the inner ocular tissues with the DFS:IR 
Figure 5.5B: Rate of elimination of DFS concentrations form Iris 
ciliary bodies (IC) at the end of 8 h post topical application. 
Conscious animal model. 
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film was significantly lower compared to the film loaded with free DFS. Thus, DFS:IR loaded 
matrix films can maintain DFS levels for prolonged period of time and may provide at least a twice 
a day application. Moreover, the IR loaded dosage form avoids the spikes in the ocular tissues 
noted with the other dosage forms including the free drug loaded matrix films. 
5.5. Conclusion:  
Ocular tissue concentrations of DFS from film demonstrated high concentrations in 
aqueous humor and iris-ciliary bodies. Although, DFS film was able to load the tissues with the 
drug, DFS-IR film showed more controlled release across the tissues. Interestingly, only the IR 
film was able to deliver the drug the posterior segment of the eye (retina-choroid). Thus, drug IR 
complexes loaded into a matrix film can be a perfect platform for an immediate and sustained 
release delivery systems. Modification of the IR-film using different resins, different concentration 
of unbound drug and drug IR complexes can be used to meet the requirement of individual drug 
release profiles. 
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APPENDIX A: DEFINITIONS OF VARIOUS TERMS USED IN CHAPTER 5: 
DICLOFENAC SODIUM AND ION EXCHANGE RESIN COMPLEX LOADED MELT 
CAST FILMS FOR SUSTAINED RELEASE OCULAR DELIVERY 
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Ion exchange resins ↔ Water insoluble cross linked polymers with ionizable groups that can be 
exchanged to form complexes. Ion exchange resin (IR) in the present study represent DuoliteTM 
AP 143/1083. 
1:1::DFS:IR ↔ 1 part by weight of DFS is bound to 1 part by weight of IR. 
1:2::DFS:IR ↔ 1 part by weight of DFS is bound to 2 part by weight of IR. 
2:1::DFS:IR ↔ 2 part by weight of DFS is bound to or used to form complexes with 1 part by 
weight of IR. 
DFS Film ↔ Matrix film with unbound/free from of DFS without any IR. 
1+1:1::DFS:IR ↔ 1 part by weight of DFS is bound to 1 part by weight of IR (for sustained 
release) and remaining 1 part by weight of DFS is in unbound or free state (for immediate release). 
For example, in a film with 1.6 mg of total DFS, 0.8 mg is bound or complexed with IR 0.8 mg of 
IR and remaining 0.8 mg of DFS is in free or unbound state. 
3+1:1::DFS:IR ↔ 1 part by weight of DFS is bound to 1 part by weight of IR (for sustained 
release) and 3 parts by weight of DFS is in unbound or free state (for immediate release). For 
example, in a film with 1.6 mg of total DFS, 0.4 mg is bound or complexed with IR 0.4 mg of IR 
and remaining 1.2 mg of DFS is in free or unbound state. 
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Graphical abstract 9.1: Development of HT film and overview of in vitro permeability, ex vivo & in vivo ocular distribution.  
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APPENDIX C: GRAPHICAL ABSTRACT FOR THE DEVELOPMENT OF DFS-IR-FILM 
USING DUOLITETM AP 143/1089 RESIN AND MELT-CAST TECHNOLOGY 
  
Graphical abstract 9.2: Development of DFS-IR-Film using DuoliteTM AP 143/1089 resin and melt-cast technology. 
1
2
0
 
 121 
 
VITA 
 
GOUTHAM R. ADELLI_________________________________________________________ 
    Faser 110    .    University, MS 38655     .     (662) 915 7641     .      gradelli@go.olemiss.edu 
 
EDUCATION: 
August, 2011 –May 2016 Joined Ph.D. Program, Department of Pharmaceutics and 
Drug Delivery, The University of Mississippi 
May 2007-May 2011 B. Pharmacy, Jawaharlal Nehru Technological University, 
India 
TEACHING EXPERIENCE:  
January, 2012 –May 2015                  Lab Instructor  
     PRCT 354 Course: Formulation and compounding lab  
     University of Mississippi 
January, 2013 –May 2014                  Instructor  
     Tablet course  
     University of Mississippi 
 
ACHEIVEMENTS/AWARDS:  
 Neuroscience Research Showcase graduate student award, April 2014, University 
of Mississippi, Mississippi 
 NIH pre-doctoral fellowship: Center of Research Excellence in Natural Products 
Neuroscience (CORE-NPN) – March 2014, University of Mississippi, Mississippi 
 Summer graduate research fellow award - May 2014, University of Mississippi, 
Mississippi 
 Ocular Drug Delivery and Disposition Focus Group graduate student award- 
AAPS, November 2013, San Antonio, Texas 
PROFESSIONAL ACITIVITES: 
 Member of Rho Chi, ARVO and AAPS 
 Teaching assistant: Formulation and compound lab 
 Instructor/assistant : Hands-on tablet course 
 122 
 
 Staff selection committee student member 
 Reviewer for AAPS PharmSciTech and Pharmaceutical research Journals 
PROFESSIONAL ACITIVITES: 
 Adelli GR, Hingorani T, Punyamurthula N, Balguri S, Majumdar S. Evaluation of 
Topical Hesperetin Matrix film for Back-of-the-Eye Delivery. Eur J Pharm 
Biopharm. 2015 Feb 26. 
 Adelli GR, Balguri S, Majumdar S. Effect of cyclodextrins on morphology and 
barrier characteristics of isolated rabbit corneas. AAPS PharmSciTech. 2015 Mar 
13. 
 Hippalgaonkar K, Adelli GR, Hippalgaonkar K, Repka MA, Majumdar S. 
Indomethacin- loaded solid lipid nanoparticles for ocular delivery: development, 
characterization, and in vitro evaluation. J Ocul Pharmacol Ther. 2013 Mar; 
29(2):216-28. doi: 10.1089/jop.2012.0069. Epub 2013 Feb 19. 
 Adelli GR, Bhagav P, Elsohly MA, Repka MA, Majumdar S. “Ocular Delivery of 
Tetrahydrocannabinol. The Handbook of Cannabis and Related Pathologies: 
Biology, Diagnosis, Treatment, and Pharmacology”. (Accepted).  
 Hingorani T, Adelli GR, Punyamurthula N, Gul W, Elsohly MA, Repka MA, 
Majumdar S. Ocular  disposition  of  the  hemiglutarate  ester  prodrug  of  ∆⁹-
Tetrahydrocannabinol  from various ophthalmic formulations. Pharm Res. 2013 
Aug; 30(8):2146-56. doi: 10.1007/s11095-013-1072-x. Epub 2013 Jun 5. 
 Goutham R Adelli, Ramesh Srirangam, Soumyajit Majumdar. Phytochemicals in 
ocular health: Therapeutic potential and delivery challenges. World J Pharmacol 
2013 March 9; 2(1): 18-34. 
 
 
